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Abstract  
 
Introduction: Placebo has been proven effective in many diseases 
but whether it is effective in the treatment of fibromyalgia, a chronic 
widespread pain condition affecting 2% of general population, is 
unknown.  
 
Objectives: [1] to determine whether placebo is effective for 
fibromyalgia; [2] to identify the possible determinants of the placebo 
effect [3] to gain knowledge around placebo effect, including nocebo 
effect and placebo response in difference conditions.  
 
Method: Literatures were searched for randomised controlled trials 
that included placebo as a treatment or comparator in people with 
fibromyalgia. The placebo effect was measured as the improvement 
of pain and other outcomes from baseline. The effect was compared 
with no treatment control group or waiting list group. Meta-analysis 
was undertaken to combine data from different studies. Subgroup 
analysis was conducted to identify possible determinants of the 
placebo effect.  
 
Results: 3375 studies were found from the literature search.  After 
scrutiny, 204 trials met the inclusion criteria. Participants who took 
placebo in the trials had significant improvement in pain, fatigue, 
sleep quality, physical function, and other main outcomes, while 
participants in the no treatment controlled group stayed unchanged. 
The effect size of placebo in pain relief is clinically moderate (ES=0.47, 
95%CI 0.37 to 0.56). The effect increased with the strength of the 
active treatment in the trials, participants¶ age and baseline pain 
severity, but decreased in women and with longer duration of disease.   
 
Conclusion: Placebo per se is effective in the treatment of 
fibromyalgia. The effect varies upon context, suggesting that the 
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treatment effect in fibromyalgia depends on context which may be 
enhanced with the alternation of non-specific or contextual factors.  
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Chapter 1 Introduction 
 
 
I¶ll discuss the current understanding of fibromyalgia (FM), including 
definition, epidemiology, diagnosis, and treatment. I¶ll then discuss 
the history and definition of placebo, possible mechanisms, clinical 
evidence of its therapeutic effect in general and placebo analgesia in 
musculoskeletal disorders to justify this study.  Finally, the aims and 
objectives of the thesis will be stated.  
 
1. Introduction to fibromyalgia  
 
1.1 Definition and history  
 
Fibromyalgia is a disorder characterised by chronic widespread 
musculoskeletal pain, fatigue, non-restorative sleep and widespread 
lowered pain threshold, (Pozgain et al., 2014) 
 
Historically the condition has been recognised under different 
diagnostic labels. The earliest descriptions that were identified in 
European literature in the late 16th century described it as widespread 
PXVFXORVNHOHWDO³DFKHVDQGSDLQV´(Inanici and Yunus, 2004). Early 
definitions of this condition were vague with almost no distinction 
between generalised and localised pain syndromes.  
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7KHWHUP³ILEURVLWLV´ZDVILUVWXVHGIRU)0E\WKH%ULWLVKQHXURORJLVW
Sir William Gowers in 1904 (Gowers, 1904). However, the concept of 
fibrositis was not clearly defined and in fact overlapped with many 
other rheumatic conditions (Table 1-1). In the mid-1970s, Smythe and 
Moldofsky defined fibrositis as a generalised pain syndrome, 
accompanied by fatigue, poor sleep, morning stiffness, aggravating 
and relieving factors, emotional distress, and multiple hyperalgesic 
tender points (Smythe and Moldofsky, 1977). The change of the 
name was inspired by the increasing evidence that there was no 
inflammation in the connective tissues of individuals with this 
condition. In 1990, the American College of Rheumatology (ACR) 
further developed this concept by publishing criteria for the diagnosis 
of  FM (Harth, 2013). One of the unique features of the ACR criteria 
is the requirement of a hyperalgesic wince-withdrawal response to 
pressure in at least 11 out of 18 defined ³WHQGHUSRLQWV´ LQDOO IRXr 
quadrants of the body (Figure 1-1). 
 
Table 1-1 Development of the concept of FM 
Study   Name used Definition/Description 
Gowers, 
1904 
Fibrositis  ³:H DUH WKXV FRPSHOOHG WR regard lumbago in 
particular and muscular rheumatism in general, as 
a form of inflammation of the fibrous tissues of the 
PXVFOHV« $QG WKXVZH PD\ FRQYHQLHQWO\
IROORZ WKH DQDORJ\ RI µFHOOXOLWLV¶ DQG WHUP LW
µILEURVLWLV¶´ 
Smythe, 
1989 
Fibrositis 
syndrome 
A generalized pain syndrome, along with fatigue, 
poor sleep, morning stiffness, aggravating and 
relieving factors, emotional distress, and multiple 
tender points. 
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Wolfe, 1990 Fibromyalgia  Widespread pain for longer than three months with 
pain on palpation at 11 or more of 18 specified 
tender points. 
Clauw, 
2001 
Fibromyalgia Individuals with chronic widespread 
musculoskeletal pain, fatigue and lowered pain 
threshold for which no alternative cause can be 
identified. 
 
Following widespread use of the ACR criteria it was realised that the 
criteria did not always perform appropriately. Data from both British 
and American studies showed that about 20% of the population that 
suffered with FM did not fulfil the ACR criteria. Conversely, some 
individuals had sufficient tender points for diagnosis but their pain 
distribution was not sufficiently widespread (Chaitow, 2009).  
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Figure 1-1 Tender points for FM diagnosis ± ACR 1990 criteria 
 
Although the concept of FM has been developed over decades, FM 
is still a difficult-to-treat disease of unknown etiology and the debate 
of its existence continues (Harth, 2013). Due to the lack of pathologic 
evidence, observable deformity, and laboratory testing, FM has 
always been disbelieved (Blom et al., 2012). Kool used the term 
³LQYDOLGDWLRQ´ to capture this phenomenon which includes non-
acceptance by others, misunderstanding, disbelief, rejection, 
stigmatization and suspicion that the problem is exaggerated (Kool et 
al., 2009).   
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FM patients may also have a difficult relationship with their health care 
providers (Hayes et al., 2010). It has been shown in the result of a 
qualitative study by Briones-Vozmediano that patients complained 
about the delay and uncertainty in making a diagnosis, delays in 
referral to numerous specialists, the inefficacy of treatment and the 
expense of some treatments (Briones-Vozmediano et al., 2013). 
Some rheumatologist will not see patients that are referred to them 
for FM or only see them once to exclude other conditions but not 
provide ongoing care (Alghalyini and Oldfield, 2008). Health providers 
also describe their experience with FM patients as difficult (Asbring 
and Närvänen, 2003). Professionals often experience uncertainty 
when dealing with this disease because of the lack of knowledge. 
Therefore, their professionalism and explanations are questioned by 
the patients (Hellstrom et al., 1998) 
 
Some doctors believe that FM is not a disease, as they often cannot 
find any underlying structural damage apart from pain. A newspaper 
article by Alex Berenson casts doubts on the existence and validity of 
FM. He reported that some doctors and patient advocacy groups 
hoped news drugs to be approved to legitimize FM but others denied 
the existence of the disease (Camerlain and Myhal, 2009). Dr. Ehrlich 
expressed his view on FM as an untenable diagnosis because ³no 
one has FM until is diagnosed´. He argued that the pain may be real 
but FM isn¶t (Ehrlich, 2003). This opinion was seconded by Dr. Hadler, 
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who argued that people who ³have exhausted their wherewithal to 
cope´ may become victims of the iatrogenic medical construct of FM 
(Hadler, 2003). This was especially true when biological model of 
medicine was taking place, where a medical diagnosis should be 
based on biological change (Benedetti et al., 2003). However, FM can 
be a useful term to describe the complex web of co-morbid symptoms 
as described above ± chronic pain, fatigue, sleep disturbance and 
cognitive symptoms. It needs to be recognized that this is a very 
heterogeneous group and different patients may arrive at this 
symptom complex in different ways (Price et al., 1999). 
 
1.2 Overview of the nature of FM  
 
According to Smythe (Smythe, 1989) FM is a generalized pain 
syndrome. The most common characteristics of FM include fatigue, 
sleep disturbance with lack of restoration in the morning, morning 
stiffness, cognitive difficulties, stress, chronic widespread pain and 
widespread hyperalgesic tender sites. As with many other medically 
unexplained somatic symptoms, there is no adequate explanation for 
FM in terms of damage or inflammation of peripheral tissues. Instead, 
investigators began to explore central neural mechanisms to explain 
this condition (Mcbeth et al., 2001b).  
 
Population-based studies have investigated the co-morbidities of FM 
and found that other conditions may co-exist with FM (Figure 1-2). 
Such co-association could be explained by a shared pathophysiology.   
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*Data collected from (Almansa et al., 2009, Balasubramaniam et al., 
2007, Cuatrecasas et al., 2010, Kurland et al., 2006, Sarmer et al., 
2002, Toda and Harada, 2010, Wolfe et al., 2005). 
 
1.3 Epidemiology of FM 
 
1.3.1 Prevalence and incidence 
 
1.3.1.1 Prevalence 
 
Population-based epidemiological studies have investigated the 
prevalence and incidence of FM. It was found that that 2% of the  
general population met ACR criteria for diagnosis of FM in Wichita, 
0 200 400 600 800
Jaw pain
Growth hormone deficiency
Temporomandibular
disorders
Depressive symptoms
Irritable bowel syndrome
Diarrhea
Chest pain
Nausea
Abdominal pain
Carpal tunnel syndrome
Prevalence per 1000 FM patients
Prevalence per
1000 FM patients
Figure 1-2 Prevalence of main co-morbidities with FM* 
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Kansas, USA  and the prevalence was reported to be 2.2% in London, 
Ontario, Canada (White et al., 1999b). FM is much more prevalent in 
women (3.4%) than men (0.5%), with a prevalence ratio of 7:1 (White 
et al., 1999b). Prevalence also increases with age.  The Canadian 
study showed that less than 1% of 18 to 30 year old women suffered 
from FM but that this figure increased to 8% of women aged 55 to 64 
(White et al., 1999b) (Figure 1-2).  
 
Similar results were reported in some western European countries. A 
study in five European countries found that FM prevalence in general 
population varies from 1.8% (95%CI, 1.7-1.9) in France to 3.8% (95% 
CI, 3.6-4.0) in Germany (Table 1-2). In the same five countries, the 
prevalence of FM in hospital clinics was higher, varying from 6% (95% 
CI, 3.2-9.4) in Spain to 25% (95% CI, 19.6-30.8) in Germany, (Branco 
et al., 2010).  
 
The socioeconomic, ethnical, environmental and cultural difference 
among the five countries may have caused the difference in FM 
prevalence (Sukenik et al., 1999b). Although geographical variations 
have been observed among patients with chronic pain (Kong et al., 
2008), direct comparison between different countries using different 
epidemiological studies is problematic. This is because these studies 
might have used different diagnostics criteria, or had different eligible 
criteria to recruit the participants. The difference in prevalence 
between countries in the above studies may not necessarily be true 
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but reflect the differences between studies. A multicentre study using 
same protocol is still required. 
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Table 1-2 Prevalence of fibromyalgia in different countries (population-based) 
Study Location Sample size Women% Mean age Prevalence (95% CI)   
Wolfe, 1995 US 3006 / 54 2.0 (1.4±2.7) 
White, 1999 Canada 3395 62 N/A 3.3 (3.2-3.4) 
Santos, 2010 Brazil 361 64 73 5.5 (5.4-5.7) 
Le Lay, 2008 UK 1500 51 / 2.8 (1.9-3.6) 
Le Lay, 2009 Russia 1610 55 / 2.1 (1.4±2.8) 
Branco, 2010 Portugal 500 51 41 3.6 (2.0-5.2) 
 
France 1014 52 45 1.4 (0.7-2.1) 
 
Italy 1000 52 47 3.7 (2.6-4.8) 
 
Germany 1002 52 45 3.2 (2.1-4.3) 
 
Spain 1001 52 43 2.3 (1.4-3.2) 
Makela, 1991 Finland 3775 52 30+ 0.75 (N/A) 
Lindell, 2000 Sweden 2425 / / 1.3 (0.8-1.7) 
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1.3.1.2 Incidence 
 
Only two epidemiological studies have studied the incidence of FM. 
Forseth followed 2498 women in South Norway for 5.5 years and 
found that the annual incidence of FM in this population was 0.58% 
(Forseth et al., 1997). Another large population-based study showed 
an age-adjusted incidence rate of 0.69% among men and 1.13% 
among women per person-years between 1997 and 2002 (Weir et al., 
2006). According to Weir, et al. (2006) the age-adjusted relative risk 
between women and men was 1.64 (Table 1-3). 
 
Table 1-3 Incidence of FM 
Study Location Design Sample 
(n) 
Age 
range 
Women% FM incidence  
Forseth, 
1997 
Norway Cohort 
study 
2038 26-55 100 0.58% per year 
Weir, 
2006 
U.S. Cohort 
Study 
62000 <65 65 0.69% per person-
years (M) 
1.13% per person-
years (F) 
 
 
1.3.2 Risk factors for developing FM 
 
1.3.2.1 Age 
 
The prevalence of FM increases with age (Pozgain et al., 
2014)(Figure 1-3). However, the prevalence tails off over the age of 
70, sharper in women. There are a few possible explanations for the 
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age effect. Firstly, FM may remit in elderly people. Secondly, people 
with FM may be more likely to die than the general population. FM 
could either be fatal itself (e.g., suicide) or be associated with other 
potentially fatal illness. Thirdly, the tail-off may be caused by the 
cohort effect, i.e., different birth cohorts may have been exposed to 
different risk factors. For example, people born in 1945 in Hiroshima 
and Nagasaki had greater leukaemia prevalence than those born in 
1935 and 1955 because of the atomic bombs (Inaba, 2009). This may 
cause the prevalence increase in early ages then decrease in the very 
old people in a cross-sectional survey. This is however unlikely for 
FM, as a sudden shift of an environmental exposure should affect 
both men and women. Considering FM as a chronic disease, the ³Wails 
RII´SUHYDOHQFHLQYHU\ROGZRPHQZLWK)0LVPRUHOLNHO\GXHWRWKH
disease itself, e.g., self-remitted when getting older.  
 
However, FM symptoms decreased with age (Cronan et al., 2002). In 
their study, older patients reported less pain, depression, illness 
impact, and better sleep quality (Cronan et al., 2002). This diminution 
in symptoms may be explained by the fact that older individuals often 
perceive their health status positively (Cockerham et al., 1983).  
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Figure 1-3 Prevalence of FM for both genders 
 
1.3.2.2 Gender 
 
Evidence concurs in every country that the prevalence is higher in 
women than in men (Table 1-4). In addition, women experience 
longer and more severe symptoms, such as more common fatigue, 
morning fatigue, hurt all over, total number of symptoms, and 
significantly more tender points than men. Symptoms for men also 
last for shorter periods of time and happen less frequently (Yunus, 
2001). The role of gender in FM symptomatology and its mechanisms 
are not fully understood yet, but are likely to involve an interaction 
between biology, psychology, and sociocultural factors (Yunus, 2002). 
 
Biological aspects of gender difference in FM have attracted much 
attention from researchers. Genetic studies in animals suggest that 
the degree of inheritance of genes involved in pain physiology may 
differ by gender, although much work needs to be done to investigate 
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such an explanation in humans (Yunus, 2001). In humans, the 
enzyme catechol-O-methyltransferase (COMT) genetic variations 
were found to contribute to pain ratings in humans in a sex-VSHFL¿F
manner. The haplotype coding for low COMT activity increased 
capsaicin-induced pain perception in women, but not men (Belfer et 
al., 2013). 
 
Physiological studies show that woman have greater sensitivity than 
men to mechanical, electrical, ischaemic and cold stimili (Fillingim 
and Maixner, 1995). Since FM becomes more prevalent in the post-
menopausal years, female hormones could play an important role. 
Oestrogen is protective against pain (Ma et al., 2011). Oestrogen may 
affect pain by modulating serotonergic neural functions, cognitive 
functions and mood (Bethea et al., 1998). Men release endorphins 
ZKLFKDFWLYDWHWKHEUDLQ¶VPX-opioid receptors more effectively than 
women (Hellstrom et al., 1998). That may partially explain why 
women in general have a lower pain threshold than men (Bragdon et 
al., 2002).  
 15 
 
Table 1-4 Prevalence by gender in FM 
Study  Location  sample  
size 
Women Mean 
age 
Prevalence 
Women                   Men 
Wolfe, 1995 US 3006 N/A 54 3.4 (2.3-4.6) 0.5 (0.0-1.0) 
White, 1999 Canada 3395 62% / 4.9 (4.8-4.9) 1.6 (1.5-1.8) 
Le Lay, 2009 Russia 1610 55% /   
Branco, 2010 Portugal  500 51% 41 5.2 (4.9-5.5) 1.8 (1.6-2.0) 
 
France 1014 52% 45 2.0 (1.7-2.3) 0.7 (0.7-0.7) 
 
Italy 1000 52% 47 5.5 (5.3-5.7) 1.6 (1.5-1.7) 
 
Germany 1002 52% 45 3.9 (3.7-4.1) 2.5 (2.4-2.6) 
 
Spain 1001 52% 43 3.3 (3.2-3.4) 1.3 (1.2-1.4) 
&,QRWSURYLGHGLQWKHRULJLQDOVWXG\ 
Citation: (Pozgain et al., 2014, Ernst and Resch, 1995) 
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Gender is associated with psychological distresses, which have also 
been shown to be important in pain modulation (Evans et al., 2013). 
Recent studies have shown that women report greater psychological 
distress and use more coping strategies than men (Goetz et al., 2008). 
Pain symptoms are likely to be influenced by socio-cultural factors as 
well. For example, it is a general belief that men should be more 
tolerant to pain than women and this belief may encourage men to 
UHSRUWOHVVSDLQWR³EHPDQO\´(Yunus, 2001).  
 
1.3.2.3 Psychosocial stress 
 
Studies have supported co-morbidity of FM and psychiatric conditions, 
such as depression, panic disorders, anxiety. It was hypothesized 
that chronic pain causes depression, or vice versa (Fulda and Wetter, 
2008). Population-based studies have shown that psychological 
distress is a strong risk factor for the future development of FM. It is 
known that different type of stress, e.g. life stress during adulthood, 
post-traumatic stress and childhood abuse are all associated with FM 
(Van Houdenhove et al., 2005, Aaron et al., 1997). However, for each 
individual type of stress, the magnitude varies (Van Houdenhove et 
al., 2005).  
 
Although most clinicians consider life stress as an association with 
FM development, prospective studies did not support this opinion 
(Van Houdenhove, 2002). Interestingly, one population-based study 
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VXJJHVWHGWKDWRQO\³LGLRV\QFUDWLF´VWUHVVRUVZLWKDVWURQJSHUVRQDO
significance may have strong impact on the development of FM (Van 
Houdenhove et al., 2002), such as high workload and the experiences 
of being bullied at work (Kivimaki et al., 2004). Post-traumatic stress 
remains a controversial factor for FM too, although some evidence 
shows an association between post-traumatic stress and FM (Cohen 
et al., 2002). It is found that traumatic stressors superimpose upon a 
long history of chronic physical and/or psychological burden and post-
event worry, catastrophizing and inactivity led by these stressors play 
an important role in FM (Zautra et al., 2004, Mclean and Clauw, 2004). 
Childhood victimization is another important type of stress that is 
highly associated with FM occurrence as an attributive risk. Report 
rates of emotional neglect or abuse, physical maltreatment, and 
sexual abuse among FM patients are higher than that of the general 
population (Mcbeth et al., 2001a, Goldberg et al., 1999). The 
SV\FKRORJLFDOWUDLWRI³VRPDWLVDWLRQ´LVD found to be a risk factor for 
future development, according to McBeth (2001). Subjects who 
display the process of somatization are at an increased risk of the 
development of FM (Mcbeth et al., 2001b).  
 
1.3.2.4 Genetic factors  
 
A strong familial component to FM has been identified in several 
studies (Verhagen et al., 2000, Shleyfer et al., 2009). FM prevalence 
of interviewed relatives of probands with FM was 18.5% and that of 
all the relatives of FM probands was estimated to be 6.4%. Both 
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figures are higher than FM prevalence in the general population 
(Verhagen et al., 2000). For first-degree relatives of probands with 
FM, the prevalence was eight-fold higher than that of the general 
population. Other symptoms that associate with FM, such as irritable 
bowel syndrome (IBS), temporo-mandibular jaw dysfunction (TMD), 
³WHQVLRQ´KHDGDFKHVDQGRWKHU UHJLRQDOSDLQ V\QGURPHVZHUHDOVR
found to be more common in family members of individuals with FM 
(Verhagen et al., 2000).  
 
Studies of twins have investigated the genetic influence on somatic 
symptoms and confirmed that these symptoms more strongly co-
aggregate in identical compared to non-identical twins and are under 
strong genetic influence. According to Kato (2006), genetic factors 
accounted for about half of the risk for developing chronic widespread 
pain (FM). Furthermore, a comparison between genders in that study 
showed no significant differences in the magnitude or type of genetic 
influence. This means that genetic factors may have the same 
predisposition to development of FM in both men and women (Kato 
et al., 2006). 
 
Although it is still unclear which specific genetic mechanisms 
predispose to FM, there are reports that certain polymorphisms of 
serotonin 5-HT2A (5-hydroxytryptamine receptor 2A), serotonin 
transporter, dopamine 4 receptor, and COMT (catecholamine O-
methyl transferase) genes occur in higher frequency in people with 
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FM. According to Cohen (2009) carriers of the COMT met/met 
genotype showed increased sensitivity to pain and this could be one 
mechanism for the role of this gene in conferring risk for FM (Cohen 
et al., 2009).  
 
One common feature of all the polymorphisms identified is that they 
are involved the metabolism or transport of monoamines. These 
compounds play a critical role in the human stress response and 
descending inhibition of upward pain neurotransmission. It is likely 
that there are many other genetic polymorphisms, involving other 
neuromodulators and monoamines, which in part determine an 
LQGLYLGXDO¶V³VHWSRLQW´IRUSDLQDQGsensory processing (Hochberg et 
al., 2010).  
 
1.4 Pathogenesis of FM 
 
1.4.1 Altered sleep physiology   
 
Sleep disturbance has been identified as a major complaint for most 
FM patients, including difficulty getting off to sleep (increased latency), 
frequent wakening, and poor quality of sleep with lack of restoration 
(Martinez-Lavin et al., 1998, Roizenblatt et al., 2001). Selective delta 
sleep deprivation causes reduced pain threshold and development of 
FM symptoms in normal volunteers (Moldofsky and Scarisbrick, 
1976). When deprived from stage-4 sleep, young healthy subjects 
experienced aching and stiffness and an overnight increase in 
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dolorimeter scores. The dolorimeter is an instrument that measures 
pain threshold and pain tolerance. The result shows that deprivation 
of restorative sleep lowers people¶s pain threshold and tolerance to 
pain.  
 
Compared with healthy controls, FM patient suffer from significantly 
lower sleep quality (p<0.04) and experience worsening of pain 
symptoms after poor sleep (Roizenblatt et al., 2001). Sleep 
disturbance is also found to be associated with lower energy and 
fatigue in patients with FM (Bradley, 2009). Frequent alpha wave 
intrusion during delta sleep (alpha delta intrusion) has been 
associated with reduced production of growth hormone and insulin-
like growth factor 1, which are needed for muscle microtrauma repair 
(Van Cauter et al., 1998).    
 
The enhanced pain, in turn, contributes to a future worsening of sleep 
TXDOLW\ZKLFKFRQVHTXHQWO\NHHSVSDWLHQWV¶IDWLJXHDWDKLJKOHYHODQG
prolongs the repair of muscle damage (Davies et al., 2008). The 
correlation between pain and sleep is supported by a large 
epidemiologic study which found that improvements in restorative 
sleep were associated with pain relief (Figure 1-4). Therefore, 
therapies which improve sleep quality for patients with chronic pain 
symptoms may also help reduce the pain (Davies et al., 2008).   
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1.4.2 Altered pain physiology 
 
Altered processing of pain appears to be a major contributor to FM 
(Abeles et al., 2007). Accumulating evidence shows that patients with 
FM have enhanced sensitivity to a wide array of stimuli, such as heat 
and cold, as well as to mechanical and ischaemic pressure (Carli et 
al., 2002). Compared with healthy controls, lower stimulus intensity is 
needed to evoke a pain response in patients with FM, (Gracely et al., 
2002). Using subjective scales and spinal nociceptive flexion reflex, 
a specific physiologic correlate for the subjective evaluation of central 
nociceptive pathways, Desmueules, et al., found a significant 
reduction in nociceptive flexion reflex threshold in FM patients  
(Desmeules et al., 2003).  
 
There is increasing evidence that FM pain is a result of augmentation 
of sensory input that is mediated by the central nervous system 
(Nielsen and Henriksson, 2007). More recent studies also found 
abnormalities in the peripheral nervous system. There is peripheral 
sensitisation, with resultant allodynia and dermatographism, spinal 
FRUG³ZLQG-XS´LQFUHDVHGOHYHOVRIWKHQHXURWUDQVPLWWHUVXEVWDQFH3
in cerebrospinal fluid, and reduced efficiency of descending inhibitory 
systems that involve the hypothalamo-pituitary axis sympathetic 
system and the growth hormone somatomedin system (Nielsen and 
Henriksson, 2007).   
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Painful symptoms of FM may also involve abnormalities in the 
descending pain inhibition pathways (Colloca and Miller, 2011). 
Normal transmission of sensory input to the brain is inhibited by the 
activation of fibres that descend from brainstem sites to the dorsal 
horn by releasing neurotransmitters that are associated with 
variations in pain and mood (Bradley, 2009). However, this function 
may be impaired in FM patients by a deficiency of these 
neurotransmitters in the central nervous system (Colloca and Miller, 
2011).  
 
Figure 1-4 Pathogenesis of FM 
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1.4.3 Psychosomatic issues  
 
As discussed before, FM may be a class of related disorders, which 
commonly co-occur in individuals. They may share physiologic 
abnormalities and genetic risks factors (Steinsbekk et al., 2007, 
Gracely et al., 2002), such as chronic fatigue syndrome, irritable 
bowel syndrome, migraine, etc. These disorders also encompass a 
number of psychiatric problems, such as attention-deficit, generalized 
anxiety disorder major depressive disorder, and obsessive-
compulsive disorder, etc (Steinsbekk et al., 2007).  
 
Environmental triggers such as exposure to stressors is a factor that 
contributes to the pathophysiology of FM (Rupp et al., 2006). Physical 
stressors at work were found to be associated with chronic 
widespread pain (Wolfe and Michaud, 2007), such as heavy lifting, 
repetitive motions, or squatting for extended periods (Lawrence et al., 
2008). Some psychosocial stressors were also found to predict the 
development of FM. The effect of mood of reported pain was studied 
by Davis. In the study, women with FM who underwent negative mood 
induction reported significantly greater increase in pain. The result 
suggests that psychosocial stress may affect the severity of pain 
associated with FM (Davis et al., 2001). 
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1.5 Diagnosis  
 
1.5.1 ACR criteria  
 
The American College of Rheumatology (ACR) criteria for the 
classification of fibromyalgia was published in 1990 (Harth, 2013). 
Since then, ACR criteria have been used widely in clinical and 
epidemiological studies. The ACR criteria were intended as 
classification rather than diagnostic criteria, although the criteria could 
be useful for clinical diagnosis as well. The 1990 ACR criteria 
emphasised two parameters in their classification: widespread 
tenderness and chronicity of symptoms. A patient would be 
diagnosed to have FM when hyperalgesia (i.e. wince/withdrawal 
response) is present in all four quadrants of the body and in at least 
11 out of 18 tender sites when digital palpation with an approximate 
force of 4kg is performed, and when multiple pain symptoms last for 
at least three months (Harth, 2013).  
 
There are a few potential pitfalls that need considering when 
clinicians use the criteria to diagnose patients with FM. First of all, the 
ACR criteria associate a single non-specific clinical feature, 
tenderness, with an entire pain syndrome (Cohen, 1993).  As 
suggested in a recent study, the anatomical regions of tenderness are 
non-specific for describing patients with diffuse pain (Katz et al., 
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2006). Secondly, there is a substantial risk of circular reasoning, as 
the criteria fail to distinguish between cause and effect (Cohen and 
Quintner, 1998). Thirdly, current understanding of FM as a diffuse 
disorder of central pain processing is not specific to FM (Cohen and 
Quintner, 1998).   
 
In 2010, ACR published an updated version of FM diagnostic criteria. 
New criteria request a patient to satisfy the following three conditions 
to be diagnosed as FM: 1) widespread pain index (WPI) =>7 and 
symptom severity (SS) scale score >= 5 or WPI 3-6 and SS scale 
score =>9, 2) symptoms have been present at a similar level for at 
least 3 months, 3) the patient does not have a disorder that would 
otherwise explain the pain. No physical or tender point examination 
is requested. The WPI scale is the number of areas in which the 
patient has had pain over the last week and it will be between 0 and 
19. The SS scale covers three FM symptoms, fatigue, waking 
unrefreshed and cognitive symptoms. Each indicates the level of 
severity over the past week (0-3). The SS scale sums up the severity 
of the 3 symptoms and the extent (severity) of somatic symptoms in 
general. The score ranges between 0 and 12.  
 
According to this definition, FM is more than just a high WPI scale but 
also high score in SS. It also recognizes that high score in symptom 
severity should be sufficient for diagnosis (Neogi et al., 2009). 
Comparison of the two classification criteria is summarised in  
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Table 1-5. ACR 2010 modification to the FM classification criteria 
allows their use in epidemiologic and clinical studies without the 
requirement for an examiner. Compared with 1990 criteria, the 2010 
version is simpler to use and administer.  
 
Table 1-5 Comparison of FM classification criteria  
 ACR 1990 ACR 2010 
Hyperalgesia site In all 4 quadrants of the body 
and in at least 11 out of 18 
tender sites 
 
Not required 
Chronicity At least 3 months At least 3 month 
Symptom severity Not specified WPI=>7; SS >= 5 or 
WPI 3-6; SS =>9, 
 
Others N/A* The patient does not 
have a disorder that 
would otherwise 
explain the pain 
*not applicable  
 
1.5.2 Clinical presentation 
 
Although ACR criteria 1990 require a minimum 11 out of 18 tender 
points, in clinical practice, patients with less tender points may also 
have a clinical presentation that is in this spectrum. The 11 point cut-
off has been criticised due to its arbitrary nature. Thus, pain and 
tenderness is more often used as the defining feature of FM (Ablin et 
al., 2008).  Doctors often diagnose someone with FM if they have the 
right symptoms, i.e. chronic widespread, multiple regional pain with 
no other explanation and fatigue.  
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1.6 Management of FM 
 
Up till now, there is no specific or effective medicine or therapy for FM. 
Doctors may use different ways to manage FM based on the main 
symptoms that the patients have. In general, all the treatments given 
to FM patients can be grouped into two categories - pharmacological 
and non-pharmacological (Table 1-6). 
 
Table 1-6 Treatments for FM 
Non-pharmacological Pharmacological 
Patient education Analgesics  
Cognitive-behavioural therapy Antidepressants 
Aerobic exercise programme Medicines that help with sleep 
Acupuncture Muscle relaxants 
Herbal medicine Anticonvulsants 
Addressing anxiety and depression Antipsychotics 
 
 
1.6.1 Non-pharmacological treatment  
 
1.6.1.1 Patient education 
 
Management of FM symptoms remains a big challenge for health 
providers as pharmacological interventions have only limited effects 
on reducing pain and other symptoms of FM (Hammond and 
Freeman, 2006). On the other hand, non-pharmacological 
approaches are attracting more and more attention from doctors, 
general practitioners, and patients themselves. Patient education, by 
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definition, is a combination of learning experiences which are 
designed to guide the patients to improve their understanding of the 
disease, their behaviours and ultimately their health status (Hill, 1997). 
The goal of patient education is to provide patients with more capacity 
to manage their condition and to improve their quality of life (Ramos-
Remus et al., 2000). Patient education in terms of providing a 
diagnostic label and explaining the nature of the condition, the 
relevant risk factors, available treatment options, and prognosis in 
terms that the individual patient can understand is also a professional 
responsibility, so should be given to every person with FM (Stewart-
Williams and Podd, 2004).  
  
In a randomised controlled trial (Verhagen et al., 2003), FM patients 
were randomised to an education course group or a control 
observation group. The education group received information on FM, 
the role of stress in the development of FM, coping, problem-solving 
techniques, assertiveness training, relaxation strategies and the 
importance of physical conditioning while the control group were 
observed while they were waiting to receive a similar intervention. 
The results showed that the education group had a better quality of 
life and self-efficacy outcomes. Helplessness, number of days feeling 
bad, physical dysfunction, and pain in the tender points decreased 
significantly.  
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Another UK study into patient education and FM management 
showed that FM patients considered this education strategy very 
helpful. Compared with the controls in a relaxation group, more 
patients in the FM education group experienced improvement in FM 
symptoms. Using the Fibromyalgia Impact Questionnaire (FIQ), 
greater changes were observed at four months for those who 
considered themselves to have improved (Hammond and Freeman, 
2006).  
 
1.6.1.2 Exercise  
 
Aerobic exercise is effective for pain relief, reducing stiffness and 
fatigue, and improving quality of life and other symptoms of FM 
(Busch et al., 2007, Assis et al., 2006, Stephens et al., 2008, Richards 
and Scott, 2002). Aerobic exercise as a treatment, either in 
combination with other therapies or on its own has been 
demonstrated to improve FM symptoms (Busch et al., 2007). Tissue 
oxygenation improvements, increased muscle endurance and high 
energy phosphate levels are suggested as the main mechanisms of 
the therapeutic effect of exercises (Valim et al., 2003, Bennett, 1989, 
O'connor and Youngstedt, 1995). Exercise also increases delta sleep 
which is reduced in FM patents (Ehrlich, 2003). Therefore a graded 
increase in aerobic exercise is a simple and very safe intervention 
that should be routinely prescribed to all FM patients (reference 
guidelines). In practice, however many patients find it hard to 
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undertake regular aerobic exercise due to their marked pain and 
fatigue.  
 
Tai chi is one type of traditional Chinese martial arts, preferentially 
practised by patients with musculoskeletal disorders and mental 
health conditions in the US. Tai chi combines meditation with slow, 
gentle and graceful movements which is thought to stimulate vital 
energy (qi) movement throughout the body. This complex exercise 
integrates physical, emotional, psychological, spiritual and 
behavioural elements (Wang et al., 2010c). Randomized controlled 
trials have been undertaken to examine the effect of tai chi in the 
treatment of FM (Wang et al., 2010b, Van Eijk-Hustings et al., 2010, 
Zhang and Wu, 2010). In one of the studies, the tai chi group had 
significantly greater improvement in some outcomes: FIQ score, 
sleep quality, 6-minute walk test and CPSS scores, compared with 
the wellness education and stretching program control group. The 
long-term effect for the tai chi group was also superior to the control 
group. Therefore, tai chi may be a promising treatment for  FM (Wang 
et al., 2010c). 
 
1.6.1.3 Sleep hygiene  
 
Sleep disturbance with non-restorative sleep is a central problem for 
FM patients. Effective management of sleep disturbance has the 
potential to improve FM symptoms. Sleep hygiene therapy was 
examined in one randomized controlled trial. Compared with usual 
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care control, sleep hygiene therapy is superior in improving patients 
sleep quality (Edinger et al., 2005a).  
 
1.6.1.4 Cognitive-behavioural therapy 
 
Cognitive behavioural therapy (CBT) was developed in the middle of 
the 20th century (Rachman, 2009). Research interest in this therapy, 
which focuses on the role of dysfunctional thought patterns in coping 
and emotional disorders, has grown rapidly in the past decades. The 
main therapeutic techniques that are employed in CBT are twofold: 
firstly, recognising and modifying dysfunctional thought patterns 
which may interfere with or have negative impacts on the treatment 
progress; and secondly, encouraging patients to change their 
behavioural patterns in order to break the vicious cycle between 
symptoms and patterns of dysfunctional performance (Bennett and 
Nelson, 2006). With the development of CBT, more methods of 
treatment have become available, which have made CBT a useful 
adjuvant therapy for many chronic conditions including FM. However, 
it is per se, a complex intervention which normally requires specific 
theory and methods to support it and it is not widely available in many 
settings  (Casale et al., 2008) 
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1.6.1.5 Acupuncture and complementary medicine 
 
Although acupuncture has been found to be effective in the 
management of pain in general (Eccles, 2007), not many clinical trials 
have assessed its potential in treating FM. Controversial results were 
reported in different studies. One randomised controlled trial found 
that acupuncture, compared with sham acupuncture in the control 
group, significantly improved symptoms of FM. Symptomatic 
improvement was not restricted to pain relief and was most significant 
for fatigue and anxiety (Martin et al., 2006b). Acupuncture is also 
found to be beneficial as adjunctive treatment to usual care for the 
FM patient in terms of reduced pain and increased quality of life 
(Targino et al., 2008). However, the opposite results have been found 
in other clinical trials. According to Assefi et al., (2005), acupuncture 
was no better than sham acupuncture at relieving pain in FM (Assefi 
et al., 2005).   
 
1.6.1.6 Electrotherapy 
 
Different types of electrotherapy have been studied in FM. Passard 
and colleagues have found that unilateral repetitive transcranial 
magnetic stimulation of the motor cortex significantly reduced pain 
and improved several aspects of quality of life including fatigue, 
morning tiredness, general activity, walking and sleep (Passard et al., 
2007a). According to Colbert, sleeping on a magnetic mattress pad 
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provides significant and clinically relevant pain relief and improved 
sleep quality in FM patients (Colbert et al., 1999). Low-frequency 
pulsed electromagnetic field therapy was studied by Sutbeyaz etc. 
They found that this therapy might improve function, pain, fatigue, and 
global status in FM patients (Sutbeyaz et al., 2009a).  
 
1.6.1.7 Balneotherapy 
 
Balneotherapy refers to the medical use of spas in hot baths and 
natural vapour baths as well as the various kinds of mud and sand. 
Several minerals are commonly found in the spa water, including 
sodium, magnesium, calcium, and iron etc (Sukenik et al., 1999a). 
Balneotherapy is known to be successful in the treatment of 
osteoarthritis and inflammatory rheumatologic disorders (Verhagen et 
al., 2007, Sukenik et al., 1999b, Verhagen et al., 2003). A few studies 
have investigated its effect against FM symptoms. Their results have 
shown that balneotherapy is effective and can be an alternative 
method in treating FM patients (Camerlain and Myhal, 2009, 
Fioravanti et al., 2007, Fioravanti et al., 2009, Evcik et al., 2002, Ardic 
et al., 2007). 
 
1.6.1.8 Summary of non-pharmacological treatments 
 
Several types of non-pharmacological treatments are available to 
treat FM patients, including educational approach, cognitive-
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behavioural therapy, exercise and complementary medicine, etc. 
Non- pharmacological treatments are effective in reducing pain and 
improving sleep quality and other self-reported outcomes, such as 
physical status, FM symptoms, physical function and psychological 
status. Some studies argue that non-pharmacological treatments are 
more effective than pharmacological treatments in FM (Lee et al., 
2011). Combination therapy that incorporates at least one 
educational therapy with one exercise therapy offers an advantage.  
In general, non-pharmacological treatments are safe to use (Millan, 
2002).  
 
1.6.2 Pharmacological treatment 
 
Pharmacological treatments of FM have been widely studied in 
clinical trials, although none of them were specifically developed for 
FM. Active research into their therapeutic potential is ongoing. Most 
commonly prescribed drugs can be categorised into anti-depressants 
or analgesics.   
 
1.6.2.1 Anti-depressants 
 
Different anti-depressants work on different parts of the brain and 
help to change the brain function in different ways but all to make 
patients feel less depressed. There are three major classes of anti-
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depressants: tricyclics (TCAs), selective serotonin reuptake inhibitors 
(SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs).    
  
A meta-analysis of 18 RCTs of antidepressants including TCAs, 
SSRIs and SNRIs shows strong evidence for the efficacy of the TCAs 
in reducing pain, sleeping disorder and fatigue. However, this class 
of antidepressants do not have a large effect size on reducing 
depression symptoms. SSRIs are proven to be effective in reducing 
pain, but the effect on fatigue and depressed mood is small. There 
was strong evidence for SNRIs in reducing pain and sleeping disorder 
(Haeuser et al., 2009).   
 
Pain and sleep-related disorders are among the most common 
complaints of FM patients. Anti-depressant drugs, although typically 
used for depression, can be also beneficial for FM patients by 
regulating these symptoms. The idea of helping FM patients with anti-
depressants is to interrupt pain cycles and to gain more restorative 
sleep. Anti-depressant drugs are prescribed at lower doses for FM 
than for depression. Amitriptyline is a typical TCA that is given at only 
low dose once at night and at that dose it works on the sleep centre 
WR LQFUHDVHGHOWDVOHHSDQGDW WKHVSLQDOFRUG WR UHGXFH ³ZLQG-XS´ 
(Goldenberg et al., 1996, Hauser et al., 2009).  
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1.6.2.2 Analgesics 
 
Chronic widespread pain is a cardinal complaint of all FM patients. 
Therefore different types of analgesics are given to patients to help 
with their symptoms. However, evidence to support the use of non-
steroidal anti-inflammatory drugs, in FM is not promising (Hayes et al., 
2010, Blom et al., 2012). Opioid analgesics like tramadol are 
considered effective in treating FM pain. Biasi found statistically 
significant improvements in self-reported pain relief in tramadol 
versus placebo treated patients (Biasi et al., 1998). The efficacy of 
tramadol was further supported by Russell who found a significantly 
lower withdrawal rate due to inadequate pain relief in the tramadol 
group than in the placebo group (Neogi et al., 2009). Other opioids 
used in FM include morphine and codeine. However, due to the 
concerns about abuse, dependency and toxicity, the use of this group 
of analgesics in FM is limited (Portenoy, 1996).  
 
1.6.2.3 Hypnotics 
 
Altered sleep physiology is the main cause of the development of FM 
and lack of restorative sleep is a common complaint of FM patients. 
Drugs that improve patients¶ sleep quality was proven to be effective 
as a treatment again FM symptoms (Boonen et al., 2005, Sicras-
Mainar et al., 2009). According to Spaeth, sodium oxybate therapy 
significantly reduced FM patients¶ pain and fatigue. Improvement in 
 37 
 
general health measured by SF-36 was also achieved (Spaeth et al., 
2012). 
 
1.6.2.4 Other drugs 
 
Anaesthetics such as lidocaine may provide small benefit when 
injected into multiple tender points (Hong and Hsueh, 1996). 
Corticosteroid is also sometimes recommended but the evidence to 
support the use of these drugs is sparse (Walsh et al., 2002).  
 
1.6.2.5 Summary of pharmacological treatments  
 
Simple analgesics and antidepressants are the most commonly used 
drugs for FM. Other drugs including gabapentidiods, dopaminergic 
agents and sleep modifiers are also used to control symptoms of FM 
(Hauser et al., 2012b). Combination of treatments is suggested if a 
single drug is ineffective.  Doses may be adjusted if needed to control 
the symptoms without increasing the side effects (Lee et al., 2011). 
As most patients with FM may have already been on multiple drugs, 
careful scrutiny of pharmacotherapy with reduction of excessive 
medication use should be considered (Schaible et al., 2011).  
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1.6.3 Economic Burden of FM  
 
With the increasing awareness of FM, a few studies have been 
conducted to estimate the economic burden of FM in different 
countries. The first study was done by White and colleagues in 
Canada in 1999. They found that, compared with  people  who did not 
suffer from FM, the ones who had FM used about twice the health 
services and about twice the costs (White et al., 1999a). In the US, 
the cost ratio was higher. The total health care cost was estimated as 
three times higher in FM patients (Berger et al., 2007). A survey in 
the Netherlands calculated the average annual cost for FM patients 
as ¼7,813 (Boonen et al., 2005). In Spain, the total costs for FM 
patient, including the use of healthcare and nonhealthcare resources 
were more than ¼5,000 higher than others. FM patient also displayed 
a higher prevalence of comorbidities, had more visits to the doctors 
and missed more days at work (Sicras-Mainar et al., 2009).     
 
FM has also caused considerable financial burden to the UK National 
Health Service (NHS). A study found that compared with the age and 
sex matched control patients with no FM from the same GP practice, 
the FM cohort had put on more burden to the NHS as FM patients 
had more co-morbidity alongside their condition, such as 
headache/migraine, depression, and sleep problems and more drug 
related adverse events. They were also more likely to be referred to 
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hospitals. Therefore, FM patient present a greater burden to the NHS 
than patients without FM (Benedetti et al., 2007).  
 
1.7 Measures of FM treatment  
 
1.7.1 Fibromyalgia impact questionnaire (FIQ) 
 
One of the most widely used measures for FM treatment is the 
Fibromyalgia Impact Questionnaire (FIQ). It was designed by 
Burckhardt originally and revised by Bennett (Bennett et al., 2009). 
The goal of this questionnaire is to assess the health status of patients 
with FM. It can be used for both clinical and research purposes. 
Concerns about the validity of this instrument include gender bias, 
because it was developed from a female dominant clinic population, 
and non-linearity of the scales (De Craen et al., 1999a).  However, 
regardless of its validation caveats, FIQ is a widely used instrument 
for measuring the impact of FM on patients and shows good 
responsiveness to change in clinical trials (De Craen et al., 1999a)   
 
1.7.2 Visual analogue scale (VAS) for pain 
 
A visual analogue scale (VAS) is often part of the questionnaires for 
FM. It is measured along a continuous line between two endpoints, 
which stand for the two extremes of the measure, eg, pain ranging 
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from 0 (ie, no pain) to 100 (extreme pain). Participants indicate a 
position along the line to quantify their pain severity (Pace et al., 1995). 
 
1.7.3 Tender points 
 
Tender points occur at many places throughout the body but for study 
purposes up to 18 specified points are used for examination for a 
wince-withdrawal response when a metered pressure is applied. The 
number of tender points is also used as a measurement of FM 
changes in clinical trials (De Pascalis et al., 2002).   
 
1.7.4 Quality of life 
 
Quality of Life (QOL) measures the general aspects of well-being, in 
various domains for patients with FM.  QOL may be measured using 
a generic QOL questionnaire such as SF-36, WHO-QOL and Euro-
QOL (Wechsler et al., 2011). It may also be measured using a 
disease-specific instrument such as FIQ (Enck et al., 2013).   While 
the former is more useful for comparisons between diseases, such as 
the impairment of QOL between patients with FM versus patients with 
cancer, the latter is more useful to catch specific outcomes due to FM 
and therefore more sensitive to change in response to treatments for 
FM.  
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1.8 Prognosis    
 
To date, all existing treatments have shown limited effect on FM. For 
many FM patients, the best thing to do after being diagnosed is to 
learn how to cope with it. Early intervention possibly could promise a 
higher chance of good prognosis. Studies show that patients being 
diagnosed and treated by general practitioners and other primary 
physicians are more likely to have larger improvement than those 
diagnosed in hospitals and other tertiary care settings (Goetz et al., 
2008). Once the symptoms of FM are severe enough to warrant 
referral to hospital specialists, improvement may be more difficult. 
Patients who begin to have symptoms after 40 are less likely to 
respond to treatment and so are patients with severe mood or 
behavioural disturbances. A lower education level has also found to 
be a risk factor for a worse prognosis. In terms of mortality, one study 
found shorter life expectancy among FM patients as a result of cancer 
(Macfarlane et al., 2001). This result was supported by who found that 
patients with widespread pain had an elevated risk of deaths from 
cancer. Furthermore, they found FM patients had higher risks of 
death from cardiovascular diseases (Walsh et al., 2002). However, it 
was not agreed by another study which concluded mortality did not 
appear to be increased in patients diagnosed with fibromyalgia, but 
the risk of death from suicide and accidents was increased (Wolfe et 
al., 2011).    
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2. Introduction to placebo and the placebo effect 
 
2.1 Definitions and history of placebo 
 
7KHZRUGSODFHERLQ/DWLQPHDQV³,VKDOOSOHDVH´The meaning of 
SODFHERZDVGHILQHGDV³DFRPPRQSODFHPHWKRGRUPHGLFLQH´LQWKH
1HZ0HGLFDO'LFWLRQDU\DQGODWHUFKDQJHGWR³DQHSLWKHWJLYHQ
to any medicine adapted more to please than to benefit thHSDWLHQW´
in the revised 4XLQF\¶V /H[LFRQ-Medicum by Hooper in 1811 (De 
Craen et al., 1999a). The placebo response is a phenomenon in 
which an inert treatment can sometimes improve a patient's condition 
simply because the person has the expectation that it will be helpful. 
Expectation plays a potent role in the placebo effect (Gensini et al., 
2005).  
 
The earliest use of placebo dates back to the 14th century. In medical 
documents, this word was first used from the late 18th century 
(Shapiro and Shapiro, 1998). Before the Second World War, placebo 
was widely used in medical practice (De Craen et al., 1999a) largely 
because there were very few effective treatments to give patients. 
However scientific evidence to support the use of placebo as a 
treatment has only been documented since the middle of the last 
century (De Craen et al., 1999a). 
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Placebo was first used in a randomised controlled trial (RCT) in 1945 
in an unpublished study funded by the MRC as a standard control to 
determine the therapeutic effect of streptomycin in pulmonary 
tuberculosis (Goetz et al., 2008). The assumption of using placebo in 
RCTs is that placebo has no treatment effect or it is inert to the 
disease of interest. However, Henry K. Beecher successfully drew 
DWWHQWLRQ WR SODFHER UHVSRQVH LQ KLV FODVVLF ZRUN HQWLWOHG ³7Ke 
3RZHUIXO 3ODFHER´ LQ 1955. He demonstrated that about 35% of 
patients with different conditions responded well to the placebo 
treatment and that this had nothing to do with a lower level of  
intelligence, as had been suggested previously (Beecher, 1955).  
 
After %HHFKHU¶VZRUNPRUHVWXGLHVZHUHXQGHUWDNHQWRH[DPLQH the 
placebo effect and the mechanism of its action in a wide variety of 
conditions including pain analgesia (Levine et al., 1978), affective 
disorders (Mayberg, 1997) and 3DUNLQVRQ¶VGLsease (De La Fuente-
Fernandez et al., 2001). A meta-analysis of 60 RCTs investigating the 
treatment of restless legs syndrome found a placebo response rate 
of 40% with a large effect for the primary outcome in most studies. It 
means that 40% of participants were much improved by taking 
placebo, (Fulda and Wetter, 2008) Placebo has also been proven to 
be effective in the treatment of chronic fatigue syndrome, though with 
a lower effect size (placebo response, 19.6%, 95%CI, 15.4 to 23.7) 
than expected and lower than in some other conditions (e.g. major 
depression, 29.7%, duodenal ulcer, 44.2%, migraine 29.0%, reflux 
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esophagitis, 26.8%) (Cho et al., 2005, Walsh et al., 2002, De Craen 
et al., 1999b, De Craen et al., 2000, Pace et al., 1995). In the 
treatment of depression, the placebo effect accounted for 68% of the 
treatment effect in studies of various types of antidepressants (Rief et 
al., 2009b). However, these studies may suffer from the same bias as 
%HHFKHU¶VVWXG\since they compared outcomes in the placebo group 
to those in a treatment group but with no observation group who were 
receiving neither of these.  Without a no-treatment observation control, 
the results may be confounded by many other factors, such as 
regression to the mean, natural history of the disease, fluctuation of 
symptoms, etc (Doherty and Dieppe, 2009, Hrobjartsson and 
Gotzsche, 2001).  
With inclusion of a third group ± DQREVHUYDWLRQRU³untreated´FRQWURO
- new studies that examined the placebo effect found different results. 
One landmark meta-analysis of RCTs in 60 conditions that had trials 
with placebo and untreated control concluded that placebo may have 
some modest effect in subjective outcomes, including pain, but not in 
objective outcomes, especially if dichotomised (Hrobjartsson and 
Gotzsche, 2001). Another more recent meta-analysis showed that 
placebo was superior to untreated controls in osteoarthritis and that 
the effect size of placebo was often greater than the additional 
specific effect of an active treatment (Zhang et al., 2008). 
Researchers distinguished the true placebo effect from perceived 
placebo effect by introducing the untreated group because this 
comparison can tell whether patients get improved by the placebo 
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effect or other non-specific effects, such as being observed in clinical 
trials ± Hawthorn effect (Mccarney et al., 2007), natural history of 
disease (Last and Adelaide, 2013) and regression to the mean 
(Stigler, 1997). In this way, the true placebo effect can be quantified 
(Ernst and Resch, 1995). More recently, a waiting list group has been 
added into randomised controlled trials to examine the placebo effect. 
In this design, people in the waiting list control group are given nothing 
but wait for the treatment at the end of the study. Using this trial 
design, Kaptchuk et al (2008) found that placebo acupuncture 
DXJPHQWHG E\ WKH SUDFWLWLRQHU¶V warmth, attention and confidence 
resulted in a significantly larger effect in the treatment of irritable 
bowel syndrome (IBS) than placebo acupuncture alonHLHWKH³ULWXDO´
needling procedure without any patient-practitioner interaction) and 
that both of these gave far better results than no treatment in an 
observation group (Kaptchuk et al., 2008a). Kapchuk et al 
subsequently demonstrated in a small proof of concept study that 
placebo given without deception could be an effective treatment for 
IBS (Suokas et al., 2012), possibly getting around the ethical dilemma 
that although we know that placebos can help patients, in clinical 
practice it is not acceptable to intentionally lie to a patient. More RCTs 
that are specially designed to examine such issues related to placebo 
are warranted.   
 
Different terms have also been used in the past 50 years to describe 
the effect related to placebo, including placebo response (Enck et al., 
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2013), and placebo effect (Wechsler et al., 2011). While there is no 
clear boundary between these terms, some differences may be 
observed during the development of the concept.  For example, 
placebo response is normally used to measure the number of people 
who respond to placebo irrespective of whether the response is due 
to placebo or other factors, such as regression to the mean or 
confounding factors (Ernst and Resch, 1995). In contrast, placebo 
effect is often used in RCTs where there is a control group, eg, no-
treatment control (Ernst and Resch, 1995).  The effect is therefore 
more specific and attributable to placebo.  Other terms have also 
been used, eg, non-characteristic (or non-specific) effect (Enck et al., 
2008), meaning response (Moerman and Jonas, 2002) and 
contextual effect, (Paterson and Dieppe, 2005). These are the terms 
used to generalise the concept of placebo and/or to encourage the 
development of contextual enhancement benefits in clinical practice 
(Doherty and Dieppe, 2009). The area is growing and the terminology 
is still evolving. 
 
2.2 Possible Mechanisms of the placebo effect 
 
Studies have shown that placebo effects exist in possibly all 
disciplines of medicine and that the mechanisms may vary. Currently, 
there are several recognised mechanisms to explain the placebo 
effect, including expectancy, classic conditioning and a 
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psychoneuroimmunological response (Stewart-Williams and Podd, 
2004, Eccles, 2007).   
 
Expectancy refers to an outcome or effect that a patient expects or 
wishes to receive from a specific intervention. For example, in pain 
studies, expectancy can be measured by asking the patient about 
how much pain relief they expect to receive after receiving the 
intervention. Expectancy is not only influenced by verbal suggestion 
but also by the previous experience and beliefs of the patient 
(Voudouris et al., 1989, Montgomery and Kirsch, 1997, Bingel et al., 
2011). A study has found that patients expected more pain reduction 
after being told they were given a strong pain killer. Expectation was 
lower in the group where patients were told they had a weak pain 
killer. Although both groups had the same placebo, these 
expectations were closely related to the magnitude of the placebo 
effect (De Pascalis et al., 2002). Emotions and anxiety are likely to 
modulate people¶s expectancies. Reduction of anxiety is likely to 
contribute to placebo effect, especially in the pain domain (Murray 
and Stoessl, 2013). Placebo treatment can significantly influence 
symptom even without concealment or deception. One study 
demonstrated that IBS patient given open label placebo had clinically 
meaningful symptom improvement that was significantly better than 
the waiting list control (Suokas et al., 2012).  
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In some studies, researchers have manipulated patient expectation 
to increase the placebo effect.  For example, researchers can pair the 
inert treatment to lower pain stimuli so that patients come to 
experience and expect pain relief. The procedure is classified as 
conditioning (Colloca and Benedetti, 2006). Conditioning can occur 
with or without a history of actual first-hand experience. Some 
patients can also build up expectation through observation of others 
(Colloca et al., 2008) The placebo effect that is produced by 
conditioning can last a few days. According to Colloca and Benedetti, 
exposure to effectiveness via conditioning elicited placebo present 
that were present after a few seconds as well as after a week (Colloca 
and Benedetti, 2006).  
 
A psychoneuroimmunological response has been suggested to 
explain certain placebo effects, especially with pain relief (Eccles, 
2007). There is some evidence that endogenous opioids are 
implicated in placebo analgesia. Levine, et al.(1978) successfully 
demonstrated that the placebo response in pain reduction could be 
blocked by the opiate antagonist naloxone (Levine et al., 1978). This 
study result was confirmed by subsequent studies using sophisticated 
investigations such as neuro-imaging (Levine and Gordon, 1984, 
Benedetti, 1996, Benedetti et al., 1995). For example, a subset of 
brain regions have been shown to be affected similarly both by 
treatment and placebo (Petrovic et al., 2002), and µ-opioid receptor 
signalling has been demonstrated to be activated E\ SDWLHQWV¶
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expectation of pain reduction (Zubieta et al., 2005). 3DUNLQVRQ¶V
disease, that results mainly from low levels of dopamine in the basal 
ganglia, is another condition that can be improved by a placebo 
response and in this case placebo associates with the release of 
dopamine in the striatum (De La Fuente-Fernandez et al., 2001). 
Some studies argue that personality traits, such as novelty seeking 
and reward responsiveness, altruism, optimism and empathy also 
play a role in the magnitude of placebo effect (Schweinhardt et al., 
2009, Scott et al., 2008a, Mackenbach, 2005, Geers et al., 2010).  
 
2.3 Placebo Analgesia  
 
Placebo analgesia refers to a situation where the administration of 
placebo could achieve a pain-relieving effect, which may be a result 
of the SDUWLFLSDQW¶V EHOLHI LQ WKH DQDOJHVLF Hffectiveness of an 
intervention (Levine et al., 1978). One of the reasons why placebo 
could contain analgesic effect is that cortical areas recruit the opioid 
dependent descending pain control system in the brainstem, which 
ultimately inhibits nociceptive processing in the dorsal horn of the 
spinal cord in a gate-control manner (Eippert et al., 2009). According 
to Eippert, et al. (2009), psychological factors can influence 
nociceptive processing in the dorsal horn of the spinal cord. Using 
neuroimaging techniques, Craggs et al (2008) demonstrated that an 
increase in neural activity which coincides with placebo analgesia is 
associated with at least two general mechanisms of pain-modulation. 
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One of the mechanisms engages affective processes during the 
whole placebo condition to aid in pain-modulation. The other 
mechanism engages cognitive processes early in the placebo time 
course that are involved in context evaluation and feedback to 
expectation-stimulus correspondence (Craggs et al., 2008). 
 
2.4 The nocebo effect  
 
A substance without medical effect does not only benefit the health 
status because of the patients¶ belief that the inert substance is 
effective, but also cause advert events (Pozgain et al., 2014). The 
nocebo effect, which is to the opposite of placebo effect, refers to the 
phenomenon in which a substance without medical effects worsens 
the health status of the person taking it as a result of negative beliefs 
(Colloca and Miller, 2011).   
 
The proven mechanisms of the placebo response can also been 
shared by the nocebo response, including reaction to expectation and 
learning by Pavlovian conditioning (Enck et al., 2008). Cutaneous 
hyperalgesia could be induced experimentally through verbal 
suggestions (Benedetti et al., 2007). According to Klosterhalfen, 
worsening of symptoms could be conditioned in a learning experiment 
with health volunteers (Klosterhalfen et al., 2009). From 
neurobiological perspectives, two neurobiological substrates have 
been shown to play a part in the nocebo effect. The secretion of 
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dopamine and endogenous opioids were found to increase in placebo 
analgesia, while the reaction decreased in placebo hyperalgesia 
(nocebo effect) (Scott et al., 2008b). Other central process, such as 
the neurohormone cholecystokinin, may also play a part in the 
nocebo response since worsening of symptoms is often associated 
with anxiety (Benedetti et al., 2006).  
 
2.5 Placebo effect in the treatment of osteoarthritis (OA) 
 
A single systematic review has examined the placebo effect in the 
treatment of OA. The study used Medline (1950±), Web of Science 
(1960±), EMBASE (1980±), Cumulative Index to Nursing and Allied 
Health Literature (CINAHL) (1982±), and Allied and Complementary 
Medicine (1985±) for literature search and found 4141 relevant 
citations. After inclusion/exclusion criteria, 198 studies were selected 
for data analysis.  
 
This study concluded that placebo is effective in the treatment of OA, 
especially for pain, stiffness and self-reported function. The size of 
this effect is influenced by the strength of the active treatment, the 
baseline disease severity, the route of delivery and the sample size 
of the study, (Nikolajsen et al., 2006). The positive relationship 
between the active treatment and placebo effect in this study explains 
that the magnitude of the placebo effect largely depend on the patient 
expectation for a treatment. The positive relationship between 
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baseline level of pain and the placebo effect suggests that placebo 
analgesia may be linear in mild to moderate pain such as OA. This is 
in fact more likely to be true as most RCTs for OA included patients 
with 30-70% pain on VAS 100 to be more sensitive to the minor 
analgesics tested. Whether placebo works for severe pain such as 
cancer pain remains unknown. This study also confirmed that needle 
placebo (e.g. sham acupuncture) produced larger effect size that oral 
tablet placebo which again relates to the patient expectation 
(Kaptchuk et al., 2006). Studies with larger sample size tended to give 
higher placebo effect (Nikolajsen et al., 2006).  This may be related 
to spectrum of participants where the larger sample size may offer 
wider patient spectrum, hence the difference between individuals.  
  
2.5 Comparison of the placebo effect   
 
Chronic pain conditions are driven by either central mechanism or 
peripheral mechanisms or both. OA is a typical disease, where pain 
is originated from peripheral joints and enhanced later by altering 
central pain mechanism (Klosterhalfen et al., 2009). Rheumatoid 
arthritis (RA) is another disease which has similar pain mechanism 
but probably more peripheral contribution (e.g., inflammation).  
Another type of pain may be caused solely by the 
alternation/abnormality of pain centre in brain or spinal cord.  FM is 
one of them (Schaible, 2007), which provides a unique pain model in 
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comparison with OA and RA to examine whether placebo works 
through central, peripheral or both to achieve its analgesia.     
 
3. Aims and objectives of the thesis 
 
The aim of this thesis is to determine whether the placebo effect exists 
in the treatment of FM and to identify factors that relate to its 
magnitude, using a systematic review of RCTs. Also a comparison 
will be undertaken to compare the placebo response to specific 
treatments used in FM to the placebo response when the same 
treatments are used in OA.  
 
The whole study has four main tasks. First of all, a systematic review 
and meta-analysis is performed to demonstrate the benefit that 
placebo can bring to FM patients. Secondly, by sub-group analysis 
and meta-regression, possible determinants of this placebo effect are 
discussed. Thirdly, adverse effect of placebo is studied to investigate 
the nocebo effect in FM. The last task is to compare the placebo in 
FM with the placebo in OA and RA. The results of the each task are 
presented in chapter 4, 5, 6, and 7, separately. More detailed 
information on the nocebo effect and different pain mechanisms and 
the rationales of doing nocebo analysis and comparison study are 
stated in chapter 6 and 7.  
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Through literature review, placebo is proven effective in different 
conditions, so the same result is expected. The size of treatment and 
route of delivery were found to be determinants of the placebo effect 
in the OA study, and they are examined as possible determinants in 
this study too. Other factors are examined based on the data 
available from all included trials. In the comparison analysis, the 
hypothesis is that placebo might work differently for pain caused 
predominantly by central mechanisms (FM) than in pain associated 
with tissue damage and peripheral nociception in OA. 
 
4. Brief summary 
This chapter provided a thorough background about FM, from its 
history, epidemiology, pathogenesis, diagnosis, current management, 
and prognosis. It is clear that FM is a central driven chronic painful 
condition. Altered sleep physiology and pain physiology play very 
important role in the development of FM. Although there is no cure to 
FM, different treatments have been studied and proven to be effective. 
Understanding on the placebo and placebo effect was also given in 
this chapter. Since the placebo is effective as a treatment to different 
conditions, it naturally brings up the question whether it is also 
effective in FM and what the determinants of the magnitude of its 
effect size. 
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Chapter 2 Methods  
 
This chapter explains the main research methods that were used in 
this study and the feasibility of choosing the methods, including ways 
of collecting data, database construction, study quality check and 
statistical analysis.  
 
In this study, a systematic review and meta-analysis was undertaken, 
which focused on the identification and analysis of RCTs of 
treatments in FM that included placebo and/or untreated arms.  
 
2.1 Systematic literature search 
 
2.1.1 Databases 
 
Electronic databases were used for the literature search, specifically 
Medline (1950±), Web of Science (1960±), EMBASE (1980±), 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
(1982±), and Allied and Complementary Medicine (1985±). For 
Medline, both PubMed and OVID databases were searched. Each 
database was searched from the date when it was initially established. 
Google search was also undertaken for specific therapies in FM, and 
the first 100 hits were examined WZ. The search was updated in Feb, 
2014 to identify new studies. 
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2.1.2 Search terms and strategies 
 
The search strategies included: [1] search for fibromyalgia; [2] search 
for randomised controlled trials (RCTs). Terms used for FM include 
fibromyalgia/ chronic widespread pain/ fibrositis. Terms used for 
RCTs included: randomised controlled trial; clinical trial; double blind 
method; single blind method; comparative study; placebo. Searches 
were combined between FM and RCTs to produce relevant citations. 
Systematic reviews and meta-analysis were searched as well to 
identify any additional studies (Appendix 1 Searching strategy). 
 
2.1.3 Other searches  
 
References from retrieved systematic reviews and RCTs were 
examined to identify studies relevant to this project. Published 
abstracts were also searched through national and international 
societies such as European League Against Rheumatism (EULAR), 
American College of Rheumatology (ACR) and British Society of 
Rheumatology (BSR). 
 
2.2 Study selection  
 
Citations were imported into Endnote X7 to remove duplications. 
Titles and abstracts were read to judge whether the studies met the 
inclusion criteria.  Full papers were obtained for further scrutiny of 
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relevant studies according to the following inclusion and exclusion 
criteria. 
 
2.2.1 Inclusion criteria 
 
Studies meeting the following criteria were included: 
x RCTs with placebo and/or untreated group 
x Studies of participants with FM 
x Studies investigating clinical outcomes such as pain, fatigue, 
sleep quality, physical function and quality of life 
x Full reports 
 
2.2.2 Exclusion criteria 
 
The following studies were excluded 
x RCTs without placebo or no-treatment control 
x RCTs with non-clinical outcome measures, eg, biochemical 
measures 
x Duplicated publications 
x Reviews, editorials or commentaries 
x Animal experiments 
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2.3 Quality assessment 
 
2.3.1 Quality of studies 
 
The Jadad score is a widely used checklist to assess the quality of a 
clinical trial. It covers three aspects, namely randomization, blinding 
and withdraws/dropouts. The Jadad score varies between zero (very 
poor) and five (rigorous).  Another well-established and commonly 
used quality assessment tool is the &RFKUDQH&ROODERUDWLRQ¶VWRROIRU
assessing risk of bias, which does not use the scoring but categorical 
system,  (Benedetti et al., 2006) .  
 
Although Jadad score has been well accepted in medical research 
and widely used, it has been criticised for being over-simplified and 
placing too much emphasis on blinding and low consistency between 
different reviewers. Allocation concealment is not included which is 
regarded as paramount to avoid bias by The Cochrane Collaboration 
(Alexopoulos et al., 2007). 
 
In this study, the Jadad checklist (Table 2-1) was used for two 
purposes, 1) to evaluate the general quality of all the included trials; 
2) to categorise the trials into different quality groups for subgroup 
analysis. To compensate the drawback of the Jadad score, allocation 
concealment was added. Blinding was future broken into healthcare 
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provider blinding, patient blinding and assessor blinding to gain better 
understanding of the placebo effect and its determinants.  
 
Details of randomisation, allocation concealment, blinding and 
withdrawal dropouts were added to the checklist for more detailed 
quality assessment (Table 2-2).  
 
Table 2-1 4XDOLW\RIWULDO-DGDG¶VFKHFNOLVW7RWDOVFRUH 
Question Yes No Unknown/NA 
1. Was the study described as randomised (This 
includes the use of words such as randomly, 
random, and randomisation)? 
1 0  
2. Was the method of random allocation appropriate 
(eg, table of random numbers, computer 
generated, etc)? 
1 -1 0 
3. Was the study described as double blind? 1 0  
4. Was the method of double blind appropriate (eg, 
identical placebo, active placebo, dummy, etc)? 
1 -1 0 
5. Was there a description of withdrawal and drop-
outs? 
1 0  
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Table 2-2 Further quality assessment 
 Random 
number 
Allocation 
concealment 
Blind 
care 
provider 
Blind 
patient 
Blind 
assessor 
Intention 
to treat 
analysis 
Yes       
No       
Unknown       
 
 
2.3.2 Risk of Bias 
 
Selection bias: All studies retrieved from the literature search were 
included regardless of the quality to avoid selection bias.  Studies of 
different qualities were analysed separately if necessary.   
 
Language bias: Non-English language databases were not 
searched.  However, there was no language restriction for the studies 
obtained through the databases listed above.  Any study meeting the 
inclusion criteria were included regardless of language to minimise 
language bias.  Translations were undertaken if needed.  
 
Publication bias: Cochrane registration (Cochrane) Clinical trials 
registration (Cochrane) and other national and international trial 
registration databases were searched for unpublished trials.  A funnel 
plot was used to examine the possibility of publication bias in each 
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analysis. The Egger statistic was used for asymmetry of the funnel 
plot (Egger et al., 1997).  
 
Heterogeneity: I2 was used to measure study heterogeneity (Higgins 
et al., 2003).  It is a measure for inconsistency among studies ranging 
from 0% to 100%.  The larger the I2 the greater is the inconsistency 
or heterogeneity of study results.  The Q test was applied to determine 
whether any heterogeneity was statistically significant (Whitehead, 
2002).   
 
2.4 Data extraction 
 
2.4.1 Development of the customised data extraction form 
 
A data extraction form was developed for the review which was used 
to collect data from each of the included studies (Appendix 2 Data 
extraction form). The information for each study was extracted 
according to the study level demographics (design, setting, year of 
publication, sample size, mean age, gender ratio, funding body etc), 
the quality assessment (randomisation, concealment, blinding, 
withdrawal, intention-to-treat analysis etc), and the outcomes (pain, 
sleep, fatigue etc).     
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2.4.2 Database development  
 
A database was developed using Microsoft Excel. Information 
concerning the study level characteristics, the quality of study and the 
outcomes was entered in the database. Different tables and 
spreadsheets were used to accommodate this information.  A unique 
study ID was assigned to each study across tables, which allowed 
querying and selection of studies for further analysis. 
 
2.5 Data validation 
 
The data were extracted by one reviewer (X.C.) from all the selected 
studies using the data extraction form. A second reviewer (K.Z.) 
randomly chose 10% of the studies and extracted the data 
independently. Agreement was examined between the two data 
extractions by another two researchers (M.D. and W.Z.). Less than 5% 
disagreement was found. The threshold of 5% was based on our 
experience under the assumption of no significant change for the 
conclusion between data with 5% disagreement and the data with full 
(100%) agreement.  
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2.6 Outcome measures 
 
2.6.1 Primary outcomes 
 
Primary outcomes of the study included pain, fatigue, sleep quality 
and physical function. The visual analogue scale (VAS) was 
commonly used to measure pain reduction. In fatigue measurement, 
The Multidimensional Fatigue Inventory (MFI) was the most 
commonly used tool. MFI is a 20-item self-report instrument designed 
to measure fatigue. It covers the following dimensions: general 
fatigue, physical fatigue, mental fatigue, reduced motivation and 
reduced activity (Ingham et al., 2011). Pain, fatigue and sleep quality 
measured by VAS were taken if reported. Other scales such as Likert 
scale and categorical scale were used when VAS was not available. 
Standardized mean difference was calculated in the meta-analysis to 
avoid heterogeneity that was caused by the usage of different 
measurement tools for the same outcome. Commonly used 
measurement tools are summarised in Table 2-3.  
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Table 2-3 Summary of commonly used measurement tools 
Outcome Measurement tool Ref 
Pain Visual analogue scale Carleton 2011 
FIQ pain Deluze 1992 
Numerical rating scale  Arnold 2010  
Brief Pain Inventory  Ginsberg 1996 
McGill Pain Questionnaire Pain 
rating index  
Arnold 2007 
Fatigue Multi-dimensional fatigue inventory Arnold 2004 
FIQ Fatigue Chappell 2008 
Visual analogue scale Kiyak 2009 
Function SF-36 Bennett 2003 
FIQ Function Hammond 2005 
Visual analogue scale Tomas-Carus 2009 
Sleep Numerical rating scale Martin 2006 
FIQ sleep disturbance Nelson 2010 
Visual analogue scale Almeida 2003 
Medical outcomes study sleep 
problems index score 
Hargrave 2012 
Depression Beck's depression inventory Branco 2010 
 
2.6.2 Secondary outcomes 
 
Secondary outcomes included quality of life (QOL), patients and 
GRFWRU¶VDVVHVVPHQWRIRYHUDOOwellbeing, and other measurements. 
The FIQ and SF36 were normally used as disease-specific and 
generic QOL instruments respectively in FM. Other QOL 
measurements were also included.  
 
FIQ is composed of 10 items. The first item contains 11 questions 
related to physical function. Each question is rated on a 4 point Likert 
type scale (0-3). Average score of all the answered questions in this 
item will be the patient¶s physical impairment score. Items 2 and 3 ask 
the patient to mark the number of days they felt well and the number 
of days they were unable to work (including housework) because of 
 65 
 
the fibromyalgia symptoms. The rest 7 items all use horizontal linear 
scale (0-10), on which patient rates pain, fatigue, depression, etc. 
After the initial scoring is completed, the first three item scores are 
subjected to normalization so that all scores range from 0 to 10. 
Therefore, the maximum possible total score of FIQ is 100.  
 
2.7 Statistical analysis 
 
Effect size (ES), that is the standardised mean difference (SMD), was 
calculated for each outcome measure.  The ES standardises the 
difference using the pooled within study standard deviation (SD) 
between groups, and therefore normalises the measure across 
studies which permits the combined analysis. However, unlike the 
natural measure of the outcome such as pain on VAS (pain ranges 
from 0 to 100 mm), ES measured the size of effect in the unit of SD.  
According to &RKHQ¶VGHILQLWLRQ(6 L.e., 20% of SD) suggests a 
small effect, ES=0.5 (i.e., 50% of SD) indicates a moderate effect, 
and ES=0.8 (80% or more of SD) means a large effect (Cohen, 1988). 
Hedges (1982) method was used to calculated ES and its 95% 
confidence intervals (CI) (Hedges, 1981). ES from baseline to the 
endpoint was calculated for each arm in the included RCTs. The 
placebo effect was defined as the difference between the ES for 
placebo and the ES for untreated control, (Nikolajsen et al., 2006). 
Heterogeneity was assessed (please see the section Risk of bias, 
page 51, for further details). A random effects model was used to 
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combine the results when heterogeneity was high, (Inaba, 2009). 
Sensitivity analysis was undertaken according to types of intention 
and type of control (placebo control, no treatment control or both).  
 
Meta-regression is a tool used in meta-analysis to examine the 
impact of moderator variables on study effect size using regression-
based techniques (Borenstein et al., 2009). In this study, it was used 
after subgroup analysis to examine the possible determinants of the 
placebo effect. 
 
2.8 Brief summary 
 
Research methods in this study were explained in this chapter. 
Systematic review and meta-analysis was chosen as the main 
research methods. Effect size of placebo was calculated as the 
standard mean difference between baseline and endpoint within the 
placebo control groups. Subgroups analysis is the main methods to 
look at the possible determinants of placebo effect and meta-
regression is further used to confirm the results.  
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Chapter 3 Study Characteristics 
 
This chapter covers all study characteristics of the included trials. The 
procedure of studies selection will be explained in details. 
Demographic characteristics of participants will be summarised at 
study level. Different treatments that were used in the trials will be 
grouped together and the quality of trials will be reported.  
 
3.1 Systematic literature search and study selection 
 
The literature search was completed and updated in February 2014. 
The type of treatment was not restricted in the search to bring out as 
many as possible trials that used different treatments. After 
summarising all treatments that were tested in the trials, each specific 
treatment was added to the search and re-run to find any missing 
trials.  
 
In total, 3375 citations were retrieved from the databases. After 
removing duplicates, 3286 citations remained. Full citations, including 
abstracts were imported into EndNote X7 and examined. 257 studies 
appeared relevant by reading abstracts and the full papers on these 
were retrieved. Subsequently, 204 of these were deemed appropriate 
and included for meta-analysis (Figure 3-1). 
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Figure 3-1 Flowchart of literature search 
 
Of the 53 studies which were excluded from the 257 eligible abstracts, 
9 did not have any clinical outcome, 31 used active interventions in 
the control groups and 8 did not have any control group. The final 5 
studies were excluded because they were secondary analysis of the 
trials whose primary outcome had already been published 
somewhere else.  
 
In order to perform meta-analysis, both the means and standard 
deviations of each outcome measure are needed. Trials that failed to 
provide suitable data were not able to enter this review. A total of 97 
eligible trials could not be included in the final data selection because 
Total citations 
3375 
3286 
Eligible abstracts 
257 
Eligible studies  
204 
53 studies were excluded because of  
 
No clinical outcome 9  
Active controlled 31 
No control group 8  
Non original article 5  
Duplicates 89 
Studies for meta-
analysis 107 
97 studies were excluded because of 
 
Insufficient data reported 
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of the lack of suitable data. Therefore, 107 trials remained for meta-
analysis.  
 
Data from all included studies were extracted using a pre-defined 
data extraction form and validated by another researcher (NA). All 
studies used either placebo or untreated group as control. One study 
that investigated magnetic therapy for FM used both placebo and 
untreated control groups (Alfano, 2001) but in the demographics 
section it is only counted once in the placebo controlled group to avoid 
duplication. 
 
3.2 Demographic characteristics of included studies 
 
Of the 107 trials included in the review, 63 used placebo and 44 used 
an untreated group as control. In total there were 10,980 participants 
in placebo controlled trials and 3,078 participants in untreated group 
controlled trials. Both placebo controlled trials and untreated group 
controlled trials had participants of a similar age range and similar 
percentage of women (Table 3-1).  
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Table 3-1 Demographic characteristics of included trials 
 
Total 
Control 
Placebo                  Observation 
No. of trials 107 63 44 
No. of participants 13968 10980 3078 
Mean age, range 
(yr) 
49.2 (29.4, 59.0) 49.0 (29.4, 59.0) 49.4 (40.8, 58.5) 
Women% 95.4 (63.7, 100) 94 (63.7, 100) 100 (74, 100) 
 
   
No. of trials reporting outcomes for 
Pain 81 47 34 
Physical function 28 14 14 
Fatigue 45 30 15 
Sleep quality 30 18 12 
 
The main symptoms of FM, such as pain, physical function 
impairment, fatigue, and sleep disturbance, were all measured in both 
placebo controlled trials and untreated group controlled trials.  
 
3.3 Geographic distribution and recruitment  
 
The USA had the largest number of trials (41/107), followed by Spain 
(12), Canada (10) and Turkey (6). All except one trial (Finchk, 2005) 
used a parallel group study design. All trials after 1990 used the 
American College of Rheumatology FM classification criteria. Trials 
that were conducted earlier than the ACR 1990 criteria used diffuse 
pain, fatigue and multiple hyperalgesic sites for FM diagnosis. Both 
criteria were considered appropriate in this review. 
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Participants were recruited entirely from the community in 17 trials, 
from general practice in 2, from hospital outpatient clinics in 53 and 
from FM Society patient groups in 4. Participants were recruited from 
two sources in 7 trials (outpatient and community, outpatient and 
patient society) and 22 trials did not specify where they recruited their 
participants. More characteristics of the included trials are 
summarised in Table 3-2.  
  
Table 3-2 Summary of other study characteristics 
 
Total 
Control 
Placebo              Observation 
Existing therapy 
Continued  30 14 16 
Stopped 32 31 1 
Unclear 45 18 27 
No. of study centres 
Single  39 19 20 
Multiple  34 31 3 
Unclear 34 13 21 
Route of delivery  
Oral 38 38 0 
Physical touch 17 17 0 
Needling* 8 8 0 
Others  44 0 44 
Funding body 
Industry 31 31 0 
Non-industry 27 8 19 
Unclear 49 24 25 
*Needling included needle injection and acupuncture  
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3.4 Types of interventions  
 
Both pharmacological and non-pharmacological interventions were 
tested in the included trials. Antidepressants were the most common 
pharmacological intervention and exercise was the most common 
non-pharmacological intervention. Other commonly investigated 
treatments included cognitive behavioural therapy (CBT), 
balneotherapy and magnetic and electrical stimulation (Figure 3-2). 
 
All pharmacological trials used placebo as control. Some physical 
intervention trials also used sham treatment as control. These 
interventions included acupuncture, magnetic field, laser, ultrasound 
and electrical current stimulation. In these studies similar technology 
was used but without the active component (e.g. electrical machines 
were turned off, non-magnetic devices were used, acupuncture 
needles did not penetrate or were used in non-acupuncture sites).        
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Figure 3-2 Types of treatments 
*CBT, cognitive-behavioural therapy; CAM, complementary and alternative medicine   
 
 
Pharmacological treatments were further categorised according to 
mechanism of action such as analgesics, antidepressants and 
hypnotics. Non-pharmacological therapies were further categorised 
as self-management, education, physical therapies (eg, exercise and 
balneotherapy), psychological therapy (eg, CBT) and complementary 
and alternative therapy (eg, herbs and acupuncture).  Many therapies 
were only studied in one trial while others were studied in just a few 
trials (Table 3-3).   
 
 
Analgesics
6%
Antidepressant 
25%
Hyponotics
3%
Acupunture
3%
Balneotherapy
5%
Other CAM*
3%
CBT* 
7%
Exercise
24%
Other physical 
intervention 
12%
Patient education
2%
Self-management
3%
Others
(Hormone, 
homeopath, 
enzyme, etc.)
7%
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Table 3-3 Summary of treatment used in all included trials 
 
Category  Treatments in included trials (No. 
of trials)  
Non-
pharmacological 
Self-management Self-management (3) 
Patient education Patient education (2) 
Exercise  Exercise (26) 
Balneotherapy Thermal bathing (3), SPA (1), 
Phytothermotheray (1), Mud pack 
bath (1) 
Other physical 
intervention** 
Current stimulation (2), 
Neurofeedback  (3), Farabloc (1), 
Ultrasound and current (1), Magnetic 
field (5), Laser (1) 
CBT* CBT (7) 
Acupuncture** Acupuncture (3) 
Other CAM* CAM (3) 
Pharmacological Analgesics** Carisoprodol, paracetamol & caffeine 
(1), Nabilone (1), pregabalin (4), 
Gabapentin (1) and Tramadol & 
acetaminophen (1). 
Antidepressants** Fluoxetine (2), Duloxetine (5), 
Milnacipran(5), Esreboxetine (2), 
Amitriptyline (5), Terguride (1), 
Tropisetron (3), Moclobemide (1), 
Citalopram (1), Dolasetron (1) and 
Paroxetine (1) 
Hyponotics** Sodium oxybate (3) 
Others** Cyclobenzaprine (1), Growth 
hormone(1), 
Dehydroepiandrosterone (1), 
Pyridostigmine (1), Alpha1-
antitrypsin (1)  Homeopath (2) 
*CAM, complementary and alternative medicine; CBT, cognitive-behavioural therapy  
** Placebo controlled trials 
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3.5 Quality assessment 
 
3.5.1 Jadad score  
 
Quality assessment was undertaken using the Jadad checklist. 
Randomization was undertaken adequately in all trials. All placebo 
controlled trials claimed to be blinded. However, two of them were 
judged not to be truly blinded based on the description in their 
methods section. Due to the nature of study, no-treatment controlled 
trials were not able to blind the participants or care providers. Most 
included trials (90%) had Jadad score >=3. More placebo controlled 
trials passed that threshold than no-treatment controlled trials (93.5% 
vs. 84.4%).  
 
3.5.2 Other quality aspects  
 
Only around half of the included trials clearly stated that they used 
intention to treat (ITT) analysis for their outcome measures. Less than 
50% (47/107) of trials had clear allocation concealment, of which 37 
were placebo controlled, and 10 were untreated group controlled 
trials. Over half of the trials (58%) contained participants who were 
blinded to treatment and all of these were placebo controlled (Table 
3-4).  Of the 63 placebo controlled studies, the majority (68.2%) 
maintained blinding of patients, care provider and assessors.  
Table 3-4 Additional assessment of study quality 
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 Total Control 
Placebo               Observation 
ITT* 
Yes 56 35 21 
No 24 11 13 
Unknown 27 17 10 
Allocation concealed 
Yes 47 37 10 
No 13 5 8 
Unknown 47 21 26 
Random number 
Yes 49 34 15 
No 6 3 3 
Unknown 52 26 26 
Blinded to: 
Patient  58 58 0 
Care provider  43 43 0 
Assessor  60 49 11 
*ITT, intention to treat analysis 
 
3.5.3 Publication bias 
 
Funnel plots were used to detect potential publication bias for the 
reporting of all major outcomes. Overall, the funnel plots are 
symmetrical for pain, fatigue, sleep, depression and FIQ total score, 
suggesting that there is no significant publication bias for these 
outcomes (Appendix 4 Publication bias). These were supported by 
the Egger test where the asymmetric tests for the 6 outcome 
measures were insignificant, (Table 3-5).  The only exception was 
physical function (Figure 3-3), where the funnel plot was asymmetric 
(p=0.0486), that is, trials with smaller placebo effects were more likely 
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to be published.  These trials normally had larger standard error (i.e., 
smaller sample size).  
 
Table 3-5 Summary of publication bias in main outcome measures 
Outcome Egger test (95%CI) P value 
Pain reduction -0.94 (-2.0, 0.14) P = 0.0859 
Fatigue -0.30 (-1.10, 0.50) P = 0.4522 
Physical function -1.47 (-2.93, -0.01) P = 0.0486 
Sleep quality -0.90 (-1.89, 0.08) P = 0.0704 
FIQ total score 0.69 (-0.75, 2.13) P = 0.3331 
Depression 0.06 (-2.17, 2.28) P = 0.9544 
Number of hyperalgesic tender sites 1.64 (-0.90, 4.17) P = 0.1939 
 
 
 
Figure 3-3 Funnel plot: physical function 
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3.6 Brief summary  
 
One hundred and seven trials were included in this study. The 
majority of participants in these trials were middle age and women. 
Various types of treatments were tested and both placebo control 
group and untreated control group were used in the trials. The quality 
of study was assessed as good in general. It all provided a great base 
for a systematic review and meta-analysis.  
 79 
 
Chapter 4 Is Placebo Effective in the Treatment of 
Fibromyalgia? 
 
In this chapter, the first main research question, whether placebo is 
effective as a treatment to FM will be answered. A direct comparison 
between the placebo group and untreated group from the same trials 
will be presented. However, the number of three arm trials which allow 
direct comparison is very limited. Indirect comparison of the placebo 
groups and untreated groups from different trials will also be used to 
demonstrate the placebo effect. The placebo effect will be examined 
in all main outcome measures to prove the existence of placebo effect. 
 
4.1 Direct comparison between placebo and untreated control 
 
Only one trial with three arms (active intervention, placebo and 
untreated control group) was found from the literature, (Alfono, 2001). 
In this trial, participants were randomised into a static magnetic fields 
treatment, sham treatment or untreated control - usual care (Table 
4-1).  
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Table 4-1 Demographic characteristics of study population 
 Static magnetic field Sham treatment Usual care 
No. of participants 37 27 17 
Mean age (years) 44.0 46.0 44.8 
Women (%) 92 96 100 
Caucasian (%) 97 100 94 
 
Sham magnetic treatment had a larger effect size on pain reduction 
and FIQ total score than usual care. The direct comparison showed 
that the participants in the sham treatment group had greater 
improvement than those in the usual care group. The effect size (ES) 
for pain reduction from baseline was 0.54 for the placebo group and 
0.06 for the usual care group. The ES for FIQ total score was 1.17 for 
the placebo group and 0.55 for the usual care group (Figure 4-1).  
This direct comparison confirms that placebo is better than untreated 
control in the clinical trial setting. However, only one study was 
available for such direct comparison. Due to the small sample size 
the 95% confident intervals were large.  
 
Figure 4-1 Effect size (95% confidence interval) on pain reduction and 
FIQ total score for treatment, placebo and untreated control groups 
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4.2 Indirect comparison between placebo and untreated control 
groups 
                                                                                                                                         
In addition, we found 62 placebo controlled trials and 44 untreated 
controlled trials. Outcomes reported in these trials were summarised 
in Table 4-2.   
 
Table 4-2 Number of trials with each outcome measure 
Outcome No. of trials (placebo) No. of trials (untreated) 
Pain reduction 47 34 
Fatigue 30 15 
Physical function 14 14 
Sleep quality 18 12 
FIQ total score  33 29 
BDI score 9 8 
Number of tender points 23 14 
 
The effect sizes (change from baseline) were pooled for placebo and 
untreated control groups respectively for different outcomes 
irrespective of whether these two groups were compared in the same 
trials or not. The results demonstrated that [1] there were substantial 
improvements from baseline (all statistically significant) for all 
outcomes in placebo groups; [2] there were, however, very little and 
non-statistically significant changes from baseline (positive/negative) 
for pain, fatigue, sleep, BDI and number of tender sites from untreated 
groups; [3] a significant worsening was observed for function score, 
whereas a significant improvement was observed for FIQ score in 
untreated control groups; [4] the magnitudes of the effect sizes in 
 82 
 
placebo groups were in general significantly greater than those in 
untreated control groups for all outcomes except for BDI. The 
comparison was made using the 95%CIs.  When the 95%CIs 
overlapped, the difference between the two groups was not 
statistically significant (Figure 4-2). 
 
Figure 4-2 Indirect comparison between placebo and untreated 
control groups 
 
4.3 Placebo effect in main clinical outcomes 
 
As placebo was better than untreated control, the following analyses 
were based on placebo group only to demonstrate detailed meta-
analysis for each clinical outcome.  
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4.3.1 Pain reduction 
 
Pain reduction is the most commonly examined outcome measure in 
clinical trials for FM. In this review 47 trials had placebo groups. In 
total 4,472 participants in the placebo groups were assessed. The 
average age of participants was 47.8 years, and over 90% of them 
were women (Table 4-3).  A statistical test could not be undertaken 
as these were study level characteristics. 
 
Table 4-3 Demographic characteristics of pain analysis 
 Placebo groups 
No. of participants 4472 
Mean age 47.8 
Women% 91.53 
 
The pain reduction due to placebo varied from study to study.   Overall, 
placebo had a medium mean effect size (ES=0.47, 95%CI 0.37 to 
0.56) in reducing pain due to fibromyalgia (Figure 4-3). The placebo 
effect became more confirmed after 2005 as all studies after that year 
had positive results. Also, studies in later years had larger sample 
size and better study quality. Compared with studies that had positive 
placebo effect, the ones that had negative results had smaller sample 
size and larger confident interval, which shows studies with better 
quality are more likely to show the true placebo effect. The studies 
that were selected for pain reduction analysis were No. 32-39, 43, 44, 
50, 52, 54, 60, 61, 63-65, 70-72, 74-79, 80, 82, 83, 86-88, 93, 96, 97, 
99, 100, 104-107 in Appendix 3 Full report of study characteristics).  
 84 
 
 
Heterogeneity in these studies was high (I2=74.3%, P < 0.0001). This 
might be explained by the fact that data were taken from trials that 
used different types of treatments. The types of placebos that were 
included in this analysis were different in shapes, doses, colours and 
administrated via different routes because they were designed to look 
exactly the same as the active treatments in order to keep the 
participants blinded.   
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Figure 4-3 Forest plot: effect size of placebo in pain reduction 
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Pooled effect size = 0.47 (95% CI = 0.37 to 0.56) 
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4.3.2 Fatigue 
 
In total, 30 placebo controlled trials measured fatigue levels.  
3DUWLFLSDQWV¶ GHPRJUDSKLF FKDUDFWHULVWLFV DJH DQG JHQGHU ZHUH
demonstrated (Table 4-4).  
 
Table 4-4 Demographic characteristics of fatigue analysis 
 Placebo groups 
No. of participants 3456 
Mean age (years) 49.2 
Women (%) 94.0 
 
A pooled analysis shows that the mean placebo effect size for 
reduction of fatigue is 0.31 (95%CI 0.26 to 0.36). Three trials had 
negative results for placebo effect, (Arnold 2002, Moldofsky 2011 and 
Almeida 2003). However, the other 27 trials all had positive results in 
reducing the level of fatigue (Figure 4-4). The studies with positive 
placebo effect had larger sample size and better quality. Low 
heterogeneity (I2=25%) was detected for this outcome (p=0.11).  The 
studies that were selected were No. 33, 36, 38-41, 53, 54, 61, 65, 71, 
72, 75-78, 82, 86-88, 91, 97, 99, 100, 101, 104, 106, 107 in Appendix 
3 Full report of study characteristics.  
 
In contrast, a pooled effect size in the untreated groups was -0.03 
(95%CI -0.15 to 0.10), suggesting that there is no improvement for 
fatigue if there was no treatment in the trials.  
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Figure 4-4 Forest plot: effect size of placebo for reduction in fatigue 
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4.3.3 Physical function 
 
Chronic pain and fatigue in FM is expected to have a negative impact 
on physical function. 14 trials had placebo groups for physical 
function (Table 4-5). This was often measured using a VAS scale, or 
part of the short form 36 and FIQ subscales.  Selected studies for this 
analysis were No. 38, 39, 53, 65, 72, 74-78, 82, 91, 104, 105 in 
Appendix 3 Full report of study characteristics.  
 
Table 4-5 Demographic characteristics of function analysis 
 Placebo groups 
No. of participants 2435 
Mean age (years) 50.5 
Women (%) 93.4 
 
Irrespective of statistical significance, one trial had a negative result 
on physical function (Finchk 2005) and one trial had a neutral result 
(Norregaard 1995). The other 12 trials all had positive results. The 
pooled mean effect size of placebo in improving physical function was 
0.27 (95%CI 0.22 to 0.33) which is a small ES (Figure 4-5). 
Heterogeneity test showed 46.7% inconsistency in this result, 
(p=0.03). 
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Figure 4-5 Forest plot pooled effect size of placebo in improving 
physical function 
 
In the untrHDWPHQW JURXSV SDUWLFLSDQWV¶ SK\VLFDO IXQFWLRQ ZDV QRW
improved.  The pooled effect size was -0.21 (95%CI -0.34 to -0.09).  
 
4.3.4 Sleep quality 
 
18 trials that had placebo evaluated sleep quality (Table 4-6).  
Table 4-6 Demographic characteristics of sleep quality analysis 
 Placebo groups 
No. of participants 1048 
Mean age (years) 50.3 
Women (%) 92.5 
 
Physical function 
-1.5 -1.0 -0.5 0.5 1.0 
Hargrave 2012 
Arnold 2012 
Branco 2010 
Arnold 2010 b 
Arnold 2010 a 
Arnold 2010 
Clauw 2008 
Kravit 2006 
Finchk 2005 
Harris 2005 
Arnold 2004 
Bennett 2003 
Russell 1999 
Norregaard 1995 
  0   
Pooled effect size = 0.27 (95% CI = 0.22 to 0.33) 
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The pooled mean effect size in the placebo groups in improving 
SDWLHQWV¶VOHHSTXDOLW\ZDV&, to 0.49). Irrespective of 
statistical significance, two out of 18 trials that measured sleep quality 
had negative results (Norregaard 1995 and Roizenblatt 2007). The 
other 16 trials all showed that placebo was effective in improving 
SDUWLFLSDQWV¶ VOHHS TXDOLW\ Negative results only occurred in small 
studies. There is 0% inconsistency found in this result, (95%CI 0% to 
43.7%, p=0.52) (Figure 4-6). The trials selected for this analysis were 
No. 31, 36, 38, 40, 52, 54, 63, 65, 68, 70, 74, 88, 91, 97, 105, and 
106 in Appendix 3 Full report of study characteristics.  
 
Figure 4-6 Forest plot: pooled effect size for placebo in improving 
sleep quality 
 
Sleep quality 
-2 -1 1 2 
Hargrave 2012 
Pauer 2011 
Nelson 2010 
Arnold 2010 b 
Jone 2008 
Arnold 2008 
Roizenblatt  2007 
Arnold 2007 
Martin 2006 
Almeida 2003 
Bennett 2003 
Colbert 1999 
Russell 1999 
Hannonen 1998 
Norregaard 1995 
Wolfe 1994 
Deluze 1992 
Vaeroy 1989 
  0   
Pooled effect size = 0.41 (95% CI = 0.32 to 0.49) 
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Participants in the untreated groups showed no change in quality of 
sleep during the study period. The pool effect size was -0.01 (95%CI 
-0.15 to 0.13).  
 
4.3.5 FIQ total score 
 
Thirty-one trials with placebo controlled in this review reported the 
FIQ total score (Table 4-7). 
 
Table 4-7 Demographic characteristics of FIQ analysis 
 Placebo groups 
No. of participants 3897 
Mean age (years) 48.3 
Women (%) 92.1 
 
The pooled effect size of placebo on FIQ total score was 0.47 (95%CI 
0.43 to 0.52). Irrespective of statistical significance, thirty-one trials all 
had positive results for placebo in terms of improving the FIQ total 
score. Only two trials with small sample size and large confidence 
intervals reported negative results (Arnold 2002, Kiyak 2009). 
Heterogeneity for this result was found to be moderate 64.3% (95% 
CI 44.6% to 74.8%, p<0.0001). Studies that were selected in this 
analysis were No. 32, 38, 40, 43, 44, 54, 60, 61, 63, 65, 68, 71-78, 
82, 83, 89, 93, 96, 99, 100 and 106 in Appendix 3 Full report of study 
characteristics.  
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Figure 4-7 Forest plot: pooled effect size of placebo in improving FIQ 
total score 
 
The effect size is significantly greater than that in the observation 
groups (pooled mean effect size, 0.17, 95%CI 0.08 to 0.26) (Figure 
FIQ total score 
-1 1 2 3 4 
Spaeth 2012 
Hargrave 2012 
Arnold 2012 
Russell 2011 
Short 2011 
Vergne-Salle 2011 
Pauer 2011 
Nelson 2010 
Distler 2010 
Branco 2010 
Arnold 2010 b 
Arnold 2010 a 
Subboyaz 2009 
Kiyak 2009 
Ali 2009 
Jone 2008 
Russell 2008 
Clauw 2008 
Chappell 2008 
Arnold 2008 
Passard 2007 
Babu 2007 
Arnold 2007 
Martin 2006 
Arnold 2005 
Arnold 2004 
Bennett 2003 
Arnold 2002 
Alfano 2001 
Heymann 2001 
Bennett 1998 
  0   
Pooled effect size = 0.47 (95% CI = 0.42 to 0.52) 
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4-7). Participants in the observation groups had no improvement in 
FIQ total score.  
 
4.3.6 Depression 
 
Nine trials with placebo controlled groups used the Beck depression 
inventory (BDI) to measure depression (Table 4-8).  
 
Table 4-8 Demographic characteristics of depression analysis 
 Placebo group 
No. of participants 1504 
Mean age (years) 49.1 
Women (%) 91.0 
 
The effect sizes of placebo varied between trials.  The heterogeneity 
was moderate (I2 = 51.7%, 95%CI 0% to 75.6%, p=0.04). The pooled 
mean effect size of placebo in BDI total score was 0.22 (95%CI 0.09 
to 0.36) (Figure 4-8). Selected studies for this analysis were No. 44, 
60, 72, 76, 78, 82, 91, 96, and 97 in Appendix 3 Full report of study 
characteristics.  
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Figure 4-8 Forest plot: pooled effect size of placebo in improving the 
BDI total score 
 
In contrast, there was no improvement in the untreated groups 
(pooled effect size, 0.08, 95%CI -0.11 to 0.28), although this was not 
statistically different from the pooled effect size in the placebo groups 
(because the two 95%CIs overlapped). The BDI score remained 
constant in the observation groups.  
 
4.3.7 Number of hyperalgesic tender sites 
 
22 placebo controlled trials measured the change in number of 
hyperalgesic tender sites. The characteristics of these trials were 
summarised in Table 4-9.   
 
 
Depression  
-0.9 -0.4 0.1 0.6 1.1 
Vergne-Salle 2011 
Branco 2010 
Arnold 2010 
Subboyaz 2009 
Ali 2009 
Clauw 2008 
Arnold 2004 
Norregaard 1995 
Wolfe 1994 
  0   
Pooled effect size = 0.22 (95% CI = 0.086 to 0.36) 
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Table 4-9 Demographic characteristics of tender point analysis 
 Placebo groups 
No. of participants 1120 
Mean age (years)  48.4 
Women (%) 91.5 
 
The pooled placebo mean effect size for reducing the number of 
hyperalgesic tender points was 0.30 (95%CI 0.21 to 0.38) (Figure 4-9). 
However, large inconsistency was found between trials (I2 =84.4%, 
95%CI 77.7% to 88.4%, p<0.0001). Selected studies for this analysis 
were No. 32-34, 40-43, 61, 65, 71-73, 84, 86, 87, 89, 91, 94, 97, 101, 
103 and 106 in Appendix 3 Full report of study characteristics.  
 
Figure 4-9 Forest plot: pooled effect size of placebo in reducing the 
number of hyperalgesic tender sites 
 
Number of tender sites 
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  0   
Pooled effect size = 0.32 (95% CI = 0.23 to 0.41) 
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In contrast, the number of hyperalgesic tender sites did not change 
from baseline to endpoint in the untreated groups.  The pooled mean 
effect size was 0.06 (95% CI -0.07 to 0.19), which was significantly 
smaller than that in the placebo groups.  
 
4.4 Brief summary 
 
 
Of the 107 trials included in this project, one had directly compared 
placebo group with untreated group and 44 had compared active with 
untreated groups. The results showed that placebo was significantly 
better than untreated group for all seven outcomes, suggesting that 
placebo is effective per se for FM.  The effect size is clinically 
significant according to CohHQ¶VGHILQLWLRQ(6 (Cohen, 1988) for 
pain and overall FM impact score, and statistically significant for 
others (Table 4-10). The clinical benefits obtained from placebo 
cannot be ignored.   
 
,QWKLVVWXG\,¶ve collected sufficient number of studies to investigate 
the placebo effect in the treatment of FM. These studies included both 
pharmacological trials and non-pharmacological trials. The 
participants that involved in the trials were mostly women and middle 
aged.   
 
The placebo effect in the treatment of FM has been proved by both 
direct and indirect comparison. Evidence shows that placebo is 
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effective and it¶s not due to natural history of the disease or regression 
to the mean.   
 
Seven outcomes were measured in the included trials. Effect size was 
calculated as the mean change from baseline to endpoint. Each 
outcome measurement was pooled to produce an overall effect size 
of placebo (Table 4-10). Pain reduction was the most widely 
measured outcome with the largest number of trials and largest 
number of participants. The placebo effect on pain reduction was also 
the largest. Six outcomes were measured with participantV¶ self-report 
and 1 was measured by physician. The effect size of placebo in all 7 
outcomes was significantly greater than that observed in the 
untreated groups.  This demonstrates that placebo is effective in FM. 
Some signals have also been picked up in the analysis. Firstly, later 
studies were more likely to produce positive results on the placebo 
effect than earlier ones. Secondly, studies with larger sample size are 
more likely to show placebo effect.    
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Table 4-10 Summary of placebo effect 
Outcome No. of trials No. of participants Poole effect size (95%CI) Publication Bias (Egger) Heterogeneity (I2) 
Pain reduction  47 4472 0.53 (0.49, 0.58) -0.94, p=0.09 73%, p<0.0001 
Fatigue 30 3465 0.31 (0.26, 0.36) -0.30, p=0.45 25%, P=0.1078 
Physical function 14 2435 0.27 (0.22, 0.33) -1.47, p=0.05 46.7%, p=0.0276 
Sleep quality 18 1048 0.41 (0.32, 0.49) -0.90, p=0.07 0%, p=0.5195 
FIQ total score 33 3897 0.47 (0.43, 0.52) 0.19, p=0.76 64.3%, p<0.0001 
BDI total score 9 1504 0.21 (0.14, 0.29) 0.06, p=0.95 51.7%, p=0.0351 
No. of hyperalgesic  tender 
sites 
23 1120 0.30 (0.21, 0.38) 1.58, p=0.24 84.4%, p<0.001 
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Chapter 5 Determinants of placebo effect  
 
5.1 Introduction to this chapter  
 
In this chapter, possible determinants of the placebo effect will be 
explored through subgroup analysis. Demographic characteristics 
such as age and gender will be considered first. Characteristics of the 
disease such as baseline severity and disease duration will also be 
examined. Other factors such as study settings, effect size of the 
active treatment etc will be discussed after. Meta-regression will be 
used in this chapter to confirm the result from subgroup analysis.  
 
5.2 Age and gender  
 
3DUWLFLSDQWV¶PHDQDJHDQGSHUFHQWDJHRIZRPHQLQHDFKWULDOZHUH
extracted for this analysis.  The mean ages were categorised into 3 
groups: <40 years (5 trials with 115 participants in the placebo 
groups), 40-50 years (29 trials with 3,474 participants), >50 years (9 
trials with 711 participants). Due to the range and distribution of 
participants¶ mean age at study level, this was the best way to break 
down age groups in order to keep each group sufficient number of 
trials. The youngest groups had the smallest placebo effect size, (ES 
0.42, 95%CI 0.16 to 0.68) followed by the middle group (ES 0.51, 
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95%CI 0.47 to 0.56), and then the oldest groups (ES 0.68, 95%CI 
0.57 to 0.79).   
 
The percentage of women in each trial also affected the placebo 
effect. In general, with the increase of the percentage of women, the 
placebo effect in pain reduction decreased. Trials with less than 80% 
women participants had the largest placebo effect size (ES 0.65, 
95%CI 0.32 to 0.98) whereas trials with 100% women participants 
had the smallest placebo effect size (ES 0.21, 95%CI 0.02 to 0.39) 
(Table 5-1).  
 
 
 101 
 
 
Table 5-1 Subgroups analysis by age and gender 
 No. of trials No. of patients ES (95%CI) Heterogeneity (I2) P Publication bias 
Age (years) 
    
  <=40  5 115 0.42 (0.16, 0.68) 66.1%, p=0.02 0.60 
  >40, <=50 29 3474 0.51 (0.47, 0.56) 64%, p<0.01 0.81 
  >50 9 711 0.68 (0.57, 0.79) 86.6%, p<0.01 0.03 
 
Women% 
     
  <80% 4 77 0.65 (0.32, 0.98) 52.6%, p=0.09 0.86 
  >80%, <90% 7 500 0.48 (0.35, 0.61) 64%, p=0.01 0.50 
  >90%,<100% 19 3342 0.57 (0.53, 0.62) 82.4%, p<0.01 0.78 
  100% 9 277 0.21 (0.02, 0.39) 42.2%, p=0.09 0.60 
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5.3 Duration of disease 
 
Duration of disease is defined as the length of time since the 
SDUWLFLSDQW¶VILUVWGLDJQRVLVRI)0XQWLOWKH\HQWHUHGWKHWULDO\HDUV
Mean duration of disease varied from 3.3 years to 17.5 years. 
Subgroup analysis was undertaken by every 5 year interval (Table 
5-2). 
 
From the table, it can be seen that the placebo effect in pain reduction 
decreased with increase in disease duration, Participants with the 
shortest duration of FM had the largest placebo effect (0.59, 95%CI 
0.51 to 0.76). Participants who had FM over 13 years had the smallest 
placebo effect (0.26, 95%CI -0.09 to 0.60).  
 
5.4 Baseline pain severity  
 
Baseline pain severity was calculated as  
 
Baseline severity = baseline score/ full score on the 
measure×100% 
 
Regardless of what scale was used to measure pain in each trial, the 
baseline pain severity was taken as the percentage of the full score 
on that scale. The lower the percentage is, the less severe the pain 
is. All trials were grouped by the baseline severity of pain in the 
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placebo groups. The group that had the lowest baseline pain severity 
(<60%) had the smallest placebo effect (ES 0.22, 95%CI 0.06 to 0.42). 
There was a tendency for increasing placebo effect with increase of 
baseline severity of pain (Table 5-3). 
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Table 5-2 Subgroup analysis by duration of disease 
 No. of trials No. of participants ES (95%CI) Heterogeneity P publication bias 
3-7 years 13 1237 0.59 (0.51, 0.67) 76.3%, p<0.01 0.30 
8-12 years 8 1208 0.56 (0.49, 0.65) 89.5%, p<0.01 0.44 
13- years 2 65 0.26 (-0.09, 0.60) N/A* N/A* 
*not applicable as only 2 trials in this group  
 
Table 5-3 Subgroup analysis by baseline pain severity 
Baseline%* No. of trials No. of participants ES (95%CI) Heterogeneity P publication bias 
<60 8 195 0.22 (0.06, 0.42) 32.26, p=0.17 0.98 
60-70 23 3,025 0.54 (0.49, 0.59) 75.3, p<0.01 0.43 
>70 15 1,147 0.56 (0.48, 0.65) 79.9%, p<0.01 0.40 
*Percentage of baseline pain value in the full score on the scale
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5.5 Chance of getting placebo 
 
Chance of getting placebo in an RCT depends on the number of 
interventions included. This is because that patients involved in the 
RCT have to be told the interventions included in the trial.  Although 
they do not know which treatment (active or placebo) they will receive, 
they do know the likelihood of getting placebo according to the 
number of groups.   Some trials had one experimental group and 
placebo group while others had more. Therefore, the chance of 
getting placebo for the participants varied across the trials. Subgroup 
analysis was performed to find out whether the chance of getting 
SODFHERKDGDQ\LPSDFWRQSDUWLFLSDQWV¶H[SHFWDWLRQDQGWKHSODFHER
effect.  
 
Of 45 trials, 32 trials had two groups (i.e., 50% chance of getting 
placebo), 7 trials had three groups (i.e., 33% chance) and 6 trials had 
4 groups (i.e., 25% chance).  The placebo effect on pain reduction 
was 0.45 (95%CI 0.40 to 0.51), 0.76 (95%CI 0.68 to 0.84) and 0.45 
(95%CI 0.34 to 0.55) respectively. It is reasonable to say the chance 
of getting placebo had little influence on placebo effect in this case 
(Figure 5-1). 
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Figure 5-1 Subgroup analysis by chance of getting placebo 
 
5.6 Effect size of active intervention 
 
Irrespective of the size of the trials, the ES of placebo increased with 
the ES of active treatment (Figure 5-2). 
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r² = 0.703821, P < 0.0001 
Figure 5-2 Correlation between effect size of active treatment and 
placebo 
 
Treatment effect size and placebo effect size were correlated in a 
linear regression test. The result shows a significant correlation 
between the effect size of active intervention and placebo.  
 
5.7 Type of active treatment 
 
Subgroup analysis was undertaken to examine whether types of 
active treatment affected the placebo effect. The results showed that 
placebo for pharmacological treatments have a larger effect size than 
the placebo/ sham treatment for non-pharmacological treatments 
(Table 5-4).  
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Table 5-4 Subgroup analysis by active treatments 
Type of treatment No. of trials No. of participants  ES of placebo (95%CI) Heterogeneity  P publication bias  
Acupuncture 3 80 0.28 (-0.04, 0.59) 0%, P=0.71 N/A 
Analgesics 2 341 0.37 (0.19. 0.50) N/A N/A 
Antidepressants 21 3085 0.57 (0.52, 0.63) 79%, p<0.01 0.27 
Muscle relaxant  2 41 0.55 (0.12, 1.00) N/A N/A 
Hypnotics  2 371 0.51 (0.37, 0.66) N/A N/A 
Magnetic field 4 487 0.30 (-0.02, 0.62) 0%, p=0.94 0.01 
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5.8 Route of delivery 
 
The most commonly used route of delivery was oral administration. 
30 trials used oral medication which included 3,878 participants in 
their placebo control groups. Two types of needling were used in the 
trials, namely, intravenous injection (2 trials with 30 participants in 
control group) and acupuncture (3 trials with 80 participants in control 
group). Intravenous injection associated with a larger placebo effect 
than acupuncture. Physical touch was also commonly used as a route 
of treatment delivery. Within this group, 4 trials used sham magnetic 
field as placebo and 2 trials used sham electrotherapy as placebo. 
Subgroup analyses were undertaken by different types of delivery 
route.  The results showed that apart from oral placebo, none of the 
other placebos had significant pain reduction effects demonstrated 
with much broader 95%CIs which included zero (Table 5-5).  This 
could be due to the small number of trials and small numbers of 
participants in each of these trials.   
 
5.9 Length of treatment period  
 
Length of treatment period was recorded by weeks in most of the 
included trials. If not, it was rounded up to the closest number of 
weeks. Subgroup analysis was done by every four weeks interval. 
The placebo effects varied but there was no clear trend that the 
placebo effect was dependent on the length of treatment (Table 5-6).
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Table 5-5 Subgroup analysis by route of delivery 
Route of delivery  No. of trials No. of participants ES (95%CI) Heterogeneity(I2) P publication bias 
Needling 
Intravenous Injection 2 30 0.47 (-0.05, 0.98) N/A N/A 
Acupuncture  3 80 0.28 (-0.04, 0.59) 0%, p=0.71 N/A 
Oral 30 3,878 0.55 (0.51, 0.60) 81.4%, p<0.01 0.07 
Physical touch 
Magnetic field 4 487 0.30 (-0.02, 0.62) 0%, p=0.94 0.01 
Electro stimulation 2 47 0.18 (-0.22, 0.58) N/A N/A 
 
 
Table 5-6 Subgroup analysis by length of treatment period 
Treatment period  No. of trials No. of participants ES (95%CI) Heterogeneity P publication bias 
ZHHNV 11 259 0.59 (0.41, 0.76) 49.3%, p=0.03 0.04 
5-8 weeks 7 266 0.35 (0.17, 0.52) 74%, p<0.01 0.48 
9-12 weeks 16 1821 0.42 (0.35, 0.48) 61.8%, p<0.01 0.83 
13-16 weeks 7 1573 0.65 (0.57, 0.72) 86.4%, p<0.01 0.41 
17- weeks 5 501 0.66 (0.53, 0.78) 78.2%, p<0.01 0.27 
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5.10 Age of the treatment  
 
The age of treatment was defined as the number of years between 
the year when a drug was first developed or approved and the year 
when the trial was published. Since treatments like acupuncture and 
magnetic field can trace back to hundreds of years ago, subgroup 
analysis by treatment age mainly focused on pharmacological 
treatments. The hypothesis is that people have higher expectation on 
new drugs. It might enhance the placebo response. Therefore, the 
placebo effect in newer drugs might be higher. The age of the 
treatment was categorised by every 10 years. However, the youngest 
two groups had larger placebo effect than the two older groups, but 
the oldest drug groups had larger placebo effect again. No certain 
tendency was found in this subgroup analysis. The age of treatment 
did not have a clear influence on the placebo effect (Figure 5-3). 
 
Figure 5-3 Subgroup analysis by age of treatment 
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5.11 Funding body 
 
Twenty-four trials had industrial funding (fully or partially) and 
contained 3,629 participants in the placebo controlled groups. Only 5 
trials did not get any industrial funding. In these non-industry funded 
trials, 151 participants were randomised into the placebo groups. 
Subgroups analysis showed placebo effect size in industry funded 
trials was 0.54 (95%CI 0.50 to 0.59), and that of non-industry funded 
trials was 0.41 (95%CI 0.17 to 0.64) (Table 5-7). 
 
5.12 Study Setting 
 
Two aspects of the study setting were considered in subgroup 
analysis, namely, the number of study centres and the method used 
to recruit participants.  
 
More trials were conducted in multi centres (26 trials, 3,932 patients) 
than single centres (16 trials, 326 patients). The ESs of placebo on 
pain reduction were 0.55 (95%CI 0.5 to 0.59) and 0.41 (95%CI 0.26 
to 0.57) respectively. There is no statistically significant difference 
between the two groups.  
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Table 5-7 Subgroup analysis by funding body 
Funding body No. of trials No. of patients ES (95%CI) Heterogeneity (I2) P publication bias 
   Industry  24  3629 0.54 (0.50, 0.59) 80.3%, p<0.01 0.05 
   Non-industry 5 151 0.41 (0.17, 0.64) 84.2%, p<0.01 0.36 
 
Table 5-8 Subgroup analysis by study setting 
 No. of trials No. of patients ES (95%CI) Heterogeneity (I2) P publication bias 
No. of centres 
    
   Single 16 326 0.41 (0.26, 0.57) 45.5%, p=0.02 0.74 
   Multiple 26 3932 0.55 (0.50, 0.59) 78.8%, p<0.01 0.28 
Participant recruit  
    
Advertisement* 5 102 0.10 (-0.18, 0.37) 0%, p=0.67 0.86 
   Referral** 33 3730 0.56 (0.51, 0.61) 76.8%, p<0.01 0.54 
*participants were recruited via advertisement in community or patient association  
SDUWLFLSDQWVZHUHUHFUXLWHGYLDGRFWRUV¶UHIHUUDO 
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Participants in all trials were recruited either through the community 
RUE\GRFWRU¶V UHIHUUDOV ,Q WRWDO WULDOVXVHGSK\VLFLDQ UHIHUUDO IRU
recruitment and recruited 3730 participants. 5 trials used 
advertisement in the community or FM patient associations and 
invited people to refer themselves to participate in the studies. 102 
participants were recruited in this way. Participants who were referred 
by their doctors had a significantly larger placebo effect for pain 
reduction, (ES, 0.56, 95%CI 0.51 to 0.61) than community recruited 
participants who only showed slight improvement from placebo (ES, 
0.10, 95%CI -0.18 to 0.37) (Table 5-8).  
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5.13 Blinding 
 
Whether participants are blinded to the treatment could greatly impact 
on the placebo effect. However, all included trials claimed they 
blinded the participants from the treatment they were given. After 
reading the trials carefully, only one trial was considered inadequately 
blinded to participants (Gur, 2002).  The effect size of placebo was 
greater in trials in which patients were apparently fully blinded (Table 
5-9). 
 
Care providers also play an important role in keeping participants 
blinded in a trial, and assessors need to be blinded to treatment to 
minimise measurement bias. In the included trials, most care 
providers and assessors appeared to be adequately blinded.  There 
was no apparent difference in placebo effect according to blinding of 
the care provider, but there was a larger placebo effect in studies 
where the assessor was not fully blinded.  
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Table 5-9 Subgroup analysis by blinding 
 No. of trials No. of participants ES (95%C) Heterogeneity P publication bias 
Care providers 
    
Yes 33 3,903 0.54 (0.49, 0.59) 78.4%, p<0.01 0.22 
No 8 289 0.58 (0.40, 0.75) 65.6%, p=0.01 0.23 
Assessors 
    
Yes 35 3,115 0.55 (0.50, 0.60) 76.7, p<0.01 0.02 
No 3 158 0.71 (0.47, 0.96) 80.2%, p=0.01 N/A 
Participants 
    
Yes 43 4,220 0.53 (0.49, 0.57) 75.6%, p<0.01 0.07 
No 1 25 1.10 (0.76, 1.42) N/A N/A 
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5.14 Meta-regression  
 
A meta-regression was performed to adjust for covariates.  Variables 
that showed a clear tendency in previous subgroup analysis (e.g. the 
proportion of women was negatively associated with the magnitude 
of the placebo effect) were chosen for the model. The Log value of 
placebo effect size was used as the dependent variable and the effect 
size of active treatments, baseline severity, proportion of female 
participants and mean age of participants were used as independent 
variables in this analysis. According to the empirical evidence of 10 
studies for each variable, 4 variables were predefined to ensure better 
power. The random-effects model was used to adjust for variance 
between studies. The analysis was undertaken using STATA 11.0.   
 
The effect size of treatment had a positive relationship with the 
placebo effect, which means the larger the effect size of the treatment 
is, the larger effect size of the placebo to this treatment is. Proportion 
of women participants had a negative relationship with the placebo 
effect. It indicates that female gender might be less responsive to 
placebo. However, due to the power of the analysis, no statistically 
significant result was found in this meta-regression (Table 5-10).  
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Table 5-10 Meta-regression 
ES.placebo Coef. Std. Err. t P>|t| [95% Conf. Interval] 
ES.treatment 0.15 0.09 1.78 0.09 -0.02 0.33 
BaselineSeverity -1.31 0.85 -1.54 0.13 -3.04 0.42 
WomenProportion -0.01 0.01 -0.93 0.36 -0.02 0.01 
MeanAge -0.001 0.02 -0.09 0.93 -0.03 0.03 
Conbined  1.94 1.27 1.53 0.14 -0.64 4.52 
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5.15 Brief summary  
 
Different variables have been considered as possible determinants of 
the placebo effect.  Age, baseline severity and effect size of the 
treatment were found to have positive association with the placebo 
effect. Female gender and disease duration were found to have 
negative association with the placebo effect. Other factors were 
considered too but no clear pattern was observed.  
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Chapter 6 Nocebo Effect in Fibromyalgia 
 
6.1 Introduction to this chapter 
 
Nocebo effect refers to the worsening of symptoms or increase in 
adverse events (AEs) that patients experience after taking a placebo. 
Nocebo includes both expected adverse effects and non-specific 
effects that cannot be related to the pharmacological action of the 
treatment. The word ³nocebo´ meaning ³I shall harm´ was first 
introduced by Kennedy in the early 1960s (Colloca and Benedetti, 
2007). The nocebo effect is the opposite of the placebo effect and has 
received wider attention from basic scientist and clinicians only 
recently (Hauser et al., 2012a). 
 
The nocebo effect shares some common features with the placebo 
effect. Expectation plays an important role on how both nocebo and 
placebo work (Kool et al., 2009). A class experiment that looked at 
the impact of people negative thoughts on their symptoms was done 
by Pfingsten and colleagues. They divided 50 people with chronic 
pain back randomly into two groups and asked them take a leg flexion 
test. They told one group that the test could increase their pain slightly 
but told the other group that the test had no impact on the pain level. 
The result showed that patient who had the negative information 
reported s tronger pain (Pfingsten et al., 2001). The negative 
psychological context surrounding the treatment and its impact on the 
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patient¶s brain and body has been investigated in a few studies 
(Bootzin and Bailey, 2005). Several neurotransmission systems may 
be involved in the production of  the nocebo effect, such as dopamine, 
opioids, beta-endorphins, and cholecystokinin within brain regions 
associated with pain and learning processes, such as the prefrontal 
cortex and hippocampus (Flaten et al., 2006). 
 
Previously, a systematic review was conducted to look at the nocebo 
effect evident in RCTs examining drug treatments for FM, (Hauser et 
al., 2012b). In this chapter, we have extended the assessment of 
nocebo effects in both pharmacological and non-pharmacological 
trials.  
 
6.2 Methods 
 
From the included studies (204 RCTs that met inclusion/exclusion 
criteria), the ones that reported any incidence of side effect were 
selected for analysis of nocebo effects. Data included information on 
the article identification and year of publication, country or countries 
where the study was performed, sample size, age and percentage of 
female participants, drug treatments, treatment duration, study design 
(parallel or crossover), number of patients treated with placebo, 
number of patients treated with placebo and experiencing any AE, 
and patients treated with placebo and withdrawn because of an AE.  
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To estimate the frequency of nocebo in these trials, we calculated the 
ratio of patients treated with placebo who reported at least one AE 
versus all placebo-treated patients. The frequency of nocebo 
dropouts was estimated as the ratio of patients treated with placebo 
who then discontinued the treatment because of intolerance versus 
all placebo-treated patients. Relative risks were calculated to find out 
whether placebo is safer than active treatments. Linear regression 
and subgroup analysis were used to determine the possible factors 
that might influence the nocebo response.  
 
6.3 Results 
 
Twenty-nine placebo controlled trials were included in the nocebo 
effect analysis (Table 6-1). Both pharmacological trials and non-
pharmacological trials were included, and all trials used placebo as 
control. In most studies gastrointestinal side effects (e.g. constipation, 
diarrhoea, and nausea), dizziness, dry mouth, and headache were 
the most commonly reported AEs.   
 
18 trials reported the number of participants who withdrew from the 
study due to intolerance of adverse effects. Meta-analysis showed 
9.0% participants in placebo controlled groups discontinued their 
treatments because of side effects (95%CI 8.0 to 10.0, I2=54%, 
p<0.05, Egger=1.82, p=0.1025) (Figure 6-1). 
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Table 6-1 Characteristics of 29 RCTs reporting nocebo effects 
Features  No. 
No. of Participants in all trials 8019 
No. of placebo treated participants  4090 
Mean age, range (yr) in placebo group 49.2 (39.3, 52.9) 
Women% in placebo group 93 (83.9, 96.7) 
Countries where the trials were carried out 
 
Brazil 1 
Canada 2 
France  1 
Germany 2 
USA 17 
Multi-nation  7 
Mean Jadad score 4.7 
Drugs studied (No. of trials) 
 
Amitriptyline 1 
Citalopram 1 
Cyclobenzaprine 1 
Dolasetron 1 
Duloxetine 4 
Esreboxetine 2 
Farabloc 1 
Fluoxetine 1 
Gabapentin 1 
Milnacipran 5 
Nabilone 1 
Paroxetine 1 
Pregabalin 5 
Sodium oxybate 1 
Terguride 1 
Tramadol/Acetaminophen 1 
Tropisetron 1 
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Figure 6-1 Proportion of participants who withdrew due to adverse 
effect in placebo groups 
 
The incidences of common adverse effects were pooled from all trials.  
In the placebo groups, the incidences of different adverse effects 
varied (Figure 6-2). Ideally, the incidence of the same set of AEs 
should have been pooled from no treatment groups to see if these 
AEs were caused by the placebo. However, none of the trials that had 
no treatment controlled groups reported such data.  
 
0.0 0.1 0.2 0.3 0.4 
Combined 0.09 (0.08, 0.10) 
Russell 2012 0.06 (0.03, 0.10) 
Vergne-Salle 2011 0.19 (0.07, 0.37) 
Paktar 2007 0.02 (0, 0.09) 
Clauw 2008 0.09 (0.07, 0.13) 
Gendreau 2005 0.04 (0, 0.18) 
Branco 2010 0.09 (0.07, 0.13) 
Arnold 2010 a 0.12 (0.07, 0.19) 
Mease 2009 0.10 (0.07, 0.15) 
Arnold 2010 b 0.02 (0, 0.06) 
Arnold 2012 0.06 (0.04, 0.10) 
Arnold 2005 0.12 (0.07, 0.19) 
Chappell 2008 0.11 (0.07, 0.17) 
Russell 2008 0.12 (0.07, 0.18) 
Arnold 2004 0.11 (0.05, 0.18) 
Crofford 2005 0.08 (0.04, 0.14) 
Pauer 2011 0.13 (0.08, 0.18) 
Mease 2008 0.06 (0.03, 0.11) 
Arnold 2008 0.11 (0.07, 0.16) 
Proportion (95% confidence interval) 
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Figure 6-2 Frequency of different adverse effect in placebo groups 
 
Relative risk was calculated to find out how safe is placebo compared 
with the treatment. For example, compared with the treatment group, 
participants in placebo controlled groups were less likely to drop out 
from the study due to adverse effects (relative risk, 0.53, 95%IC 0.47 
to 0.60) (Figure 6-3).  
0.00% 2.00% 4.00% 6.00% 8.00% 10.00% 12.00% 14.00%
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Diarrhoea
Vomiting
Nausea
Dizziness
Drowsiness
Insomnia
Dry mouth
Fatigue
Headache
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Figure 6-3 Relative risk of dropouts due to adverse effect in placebo 
group versus treatment group 
 
 
The similar result was also found in all commonly reported adverse 
effects (Table 6-2).  
0.01 0.1 0.2 0.5 1 2 5 10 100 
Russell 2012 0.38 (0.20, 0.72) 
Vergne-Salle 2011 5.61 (0.97, 34.57) 
Paktar 2007 0.25 (0.04, 1.60) 
Russell 2008 1.17 (0.54, 2.55) 
Mease 2009 0.53 (0.33, 0.83) 
Gendreau 2005 0.16 (0.03, 0.89) 
Clauw 2008 0.48 (0.34, 0.69) 
Chappell 2008 0.61 (0.36, 1.03) 
Branco 2010 0.43 (0.30, 0.60) 
Arnold 2012 0.34 (0.20, 0.57) 
Arnold 2010 b 0.27 (0.08, 0.89) 
Arnold 2010 a 0.78 (0.59, 1.04) 
Arnold 2005 0.55 (0.30, 0.99) 
Arnold 2004 0.62 (0.31, 1.22) 
Crofford 2005 0.59 (0.29, 1.22) 
Pauer 2011 0.49 (0.31, 0.77) 
Mease 2008 0.80 (0.39, 1.64) 
Arnold 2008 0.41 (0.25, 0.65) 
Combined 0.53 (0.47, 0.60) 
Relative risk (95% confidence interval) 
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Table 6-2 Relative risk of adverse effects in placebo groups compared with treatment groups 
Adverse effect No. of trials Relative risk (95%CI) Heterogeneity P
 Publication bias 
Constipation  16 0.25 (0.20, 0.30) 21.1% 0.46 
Dizziness 20 0.46 (0.34, 0.63) 72.5% 0.64 
Dry mouth 16 0.40 (0.26, 0.64) 65.5% 0.18 
Fatigue 8 0.72 (0.54, 0.94) 0% 0.52 
Headache 20 0.85 (0.76, 0.95) 53.9% 0.62 
Hot flush  4 0.24 (0.10, 0.59) 70.2% 0.01 
Nausea 22 0.58 (0.48, 0.69) 53.6% 0.41 
Palpitation  5 0.45 (0.30, 0.66) 0% <0.05 
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Linear regression shows that frequency of adverse effects in the placebo 
groups is higher when that in the treatment groups is higher (Figure 6-4).   
 
 
r2=0.24, P < 0.01 
Figure 6-4 Linear regression of adverse events in treatment and 
placebo groups 
 
When recruiting participants into their trials, the researchers need to 
explain all the possible adverse effects that the participants may 
experience from the treatment under study. Therefore, the participants 
might have had some expectation for certain types of adverse effects, 
even if they are randomised to placebo.  
 
0.0 0.2 0.4 0.6 
0.0 
0.2 
0.4 
0.6 
N 
M 
Prevalence of AE in treatment 
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To further confirm whether nocebo effect goes with active treatment 
adverse effect, the British National Formulary (2010) was used to check 
for the common adverse effects of the included treatments. Four drugs 
(Cyclobenzaprine, Milnacipran, Tropisetron, and Tramadol) could not be 
found in the book and therefore, the US Food and Drug Administration 
official website was used to find relevant information (Appendix 5 
Common adverse effects by treatment). 
 
All included trials were then re-grouped according to treatment side effect 
profile of the study medication. Group A comprised the trials that used 
treatments which share a similar type of AE and group B comprised trials 
that used treatments which do not have this type of AE. The subgroup 
analysis was done to compare the AE incidence between these two 
groups (Table 6-3). According the guidance for patient information sheet 
& consent form, for any new drug or procedure that is to be studied in a 
clinical trial, researchers should explain to the patients the possible AEs 
and report them if the patients suffer any of these AEs or any other 
symptoms. The known AEs should be explained in terms that the patients 
will clearly understand. If the drug is relatively new, the researchers 
should inform the patients that there may be unknown AEs (Burns et al., 
2005). Therefore, the hypothesis of this sub-group analysis is that the 
patients¶ consent form informed all participants of the possible AEs they 
might have from the study treatment and built up expectation of such AEs 
from the participants.  Consequently, the frequency of such AEs would 
be higher than that in the trials which used treatment without such AEs.  
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Except for nausea, Group A had no more expected nocebo effects than 
group B. Therefore, no clear conclusion can be draw based on the 
subgroup analysis.  
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Table 6-3 Subgroup analysis by type of adverse effect 
 No. of trials Proportion (95%CI) Heterogeneity  P
 publication  
Constipation  
    
Group A* 9 3.9%, (3.0-5.0) 56%, p<0.05 0.07 
Group B** 7 3.2%, (2.5-4.1) 32.5%, p>0.05 0.28 
Diarrhoea 
    
Group A  2 6.9%, (4.1-10.4) N/A*** N/A 
Group B 8 6.5%, (5.4-7.6) 4.1%, p>0.05 <0.05 
Nausea 
    
Group A 16 13.3%, (12.2-14.5) 88%, p<0.05 0.02 
Group B 7 5.5%, (3.9-7.3) 52.3%, p>0.05 0.06 
Dizziness 
    
Group A 10 6.7%, (5.6-7.8) 51.5%, p<0.05 0.50 
Group B 10 6.8%, (5.7-8.1) 79.8%, p<0.05 <0.05 
Drowsiness  
    
Group A 4 4.7%, (3.1-6.7) 75.8%, p<0.05 0.12 
Group B 6 5.4%, (3.8-7.2) 0%, p>0.05 0.28 
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Insomnia 
    
Group A 5 7.6%, (6.4-8.9)  54%, p>0.05 0.78 
Group B 7 6.5%, (4.8-8.6) 45.2%, p>0.05 0.05 
Dry mouth 
    
Group A 12 4.0%, (3.1-5.2) 79.7%, p<0.05 <0.05 
Group B 4 4.8%, (3.3-6.6) 88.3%, p <0.05 0.32 
Headache 
    
Group A 9 12.8%, (11.5-14.2) 58.3%, p<0.05 0.83 
Group B 12 11.2%, (9.6-12.8) 89.3%, p<0.05 <0.05 
*Group A, trials that used the treatments which are likely to give patients the adverse effect as expected according to British National Formulary or FDA 
**Group B, trials that used the treatments which are not likely to give patients the adverse effect as expected according to British National Formulary or FDA 
***not applicable  
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6.4 Discussion 
 
In brief, in all the 29 included trials, AEs were observed in both 
treatment groups and placebo groups. As there was no untreated 
control group, the nocebo effect cannot be confirmed. The types of 
AEs that were reported included both expected adverse effects and 
non-specific effects cannot be directly related to the use of placebo, 
some of which may be part of the symptoms of FM. Overall, about 9% 
of participants dropped out in the placebo groups.  Whether this is 
due to the use of placebo remains unknown. However, compared with 
the active treatment, the placebo was 2-times safer (e.g., only 50% 
drop-out rate of the treatment). The magnitude of the nocebo effect 
in FM was influenced by the active treatment. When the active 
treatment was more likely to cause AEs, the frequency of AEs in the 
placebo group was higher. 
 
Similar results were found in FM drug trials by Häuser and Mitsikostas 
(Hauser et al., 2012b, Mitsikostas et al., 2012).  However, only 
frequency of AEs was measured for the placebo group only.  Whether 
these AEs are due to placebo remains to be confirmed. In this study, 
discontinuation due to the given placebo was observed. According to 
Myers et al, communicating the possible AEs of a given treatment 
could lead to participants¶ withdrawal from the trial (Myers et al., 1987).  
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6.5 Caveats and future work 
 
Some signals of the nocebo effect have been observed in the trials. 
However, caveats in this study are obvious. Firstly, to fully establish 
the nocebo effect in FM, it requires an untreated control group, or 
knowledge of the background incidence of each AE in the disease 
population. The true nocebo effect can only be quantified as all the 
negative effects in the placebo group minus non-specific factors such 
as symptoms from the disease or comorbid conditions and AEs from 
accompanying medications (Colloca et al., 2008).  
 
Secondly, in a clinical trial, the methods used for recording AEs could 
have an impact on the type and the frequency of AEs reported. 
According to Rief, patients report more AEs when given a standard 
list of symptoms than when they report them spontaneously (Rief et 
al., 2009a). Therefore, the incidence of AEs reported might have been 
slightly different from the reality.   
 
Thirdly, in the attempt to make a sub-group analysis, the patient¶s 
information sheet and consent forms that were used in the trials were 
not available. Therefore, we can¶t exclude the possibility that some 
AEs were not mentioned to the participants and consequently altered 
the expectation of certain AEs. It would also be very helpful to know 
the participant information sheet in each trial to examine the specific 
information that participants receive with respect to possible side-
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effects. The result from this analysis was not significantly different 
between two groups and was not the most robust way of doing so. 
However, as in a systematic review, that was the best we could do.  
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Chapter 7 Cross Disease Comparison 
 
7.1 Introduction to this chapter 
 
Many rheumatologic conditions are associated with chronic pain. 
Some conditions are non-inflammatory, e.g. fibromyalgia (FM) and 
some are systemic inflammatory, e.g. rheumatoid arthritis (RA) (Lee 
et al., 2011). The pain mechanisms in different conditions vary, 
depending on the condition as well as individual factors. There are 
two main pain mechanisms of chronic pain, namely, peripheral 
mechanisms and central mechanisms (Schaible, 2007) .  
 
Peripheral pain mechanisms play important roles in both 
osteoarthritis (OA) and RA. This type of pain mechanisms stem from 
abnormalities in the peripheral nerves. Enhanced pain sensitivity in 
local areas is often the result of peripheral pain mechanisms 
(Schaible et al., 2011).  In contrast, central pain mechanisms work on 
the level of the central nerves system, leading to enhanced 
widespread pain sensitivity. It augments the central pain processing 
so patients would feel increased pain in response to normally painful 
stimuli (hyperalgesia) or non-painful stimuli (allodynia). The typical 
chronic pain condition is FM (Millan, 2002). 
 
The placebo effect has been confirmed in many conditions, such as 
headache (Harden et al., 1996), Parkinson¶s disease (Lidstone et al., 
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2010), and depression (Brown, 1994)etc. A recent systematic review 
and meta-analysis that included both placebo and untreated control 
groups confirmed the existence of the placebo effect in the treatment 
of OA (Zhang et al., 2008). In this review, the placebo effect was 
examined in RCTs that studied a wide range of both pharmacological 
and non-pharmacological interventions. Overall, the effect size of 
placebo analgesia in OA was 0.51 (95%CI, 0.46, 0.55). That is 
significantly higher than the untreated group (0.03, 95%CI, -0.13, 
0.18). In the direct comparison among trials with placebo and 
untreated groups, the difference between placebo (0.77, 95%CI, 0.65, 
0.89) and untreated groups (-0.08, 95%CI, -0.65, 0.48) was 
significant. This review also found some potential determinants of the 
placebo response in OA. The higher the ES of treatment is the great 
the placebo response is. Higher baseline pain produced higher 
placebo effect. The more invasive the treatment is administrated, the 
larger placebo response it can induce (Zhang, et al., 2008).  
 
In this present review of placebo effect in FM, similar results were 
found. Both direct and indirect comparison between placebo and 
untreated groups confirmed that placebo response occurred in FM. 
The ES of treatment and baseline pain severity were also shown as 
potential determinants of the placebo effect. However, whether 
placebo works differently for different types of pain such as FM, OA 
and OA remains unknown. It is well known that pain FM is largely 
driven by central pain mechanism, whereas pain in RA is largely 
 138 
 
driven by inflammation. Pain in OA, however, is driven by both 
peripheral and central mechanisms. These three types of pain 
provide an excellent opportunity to examine the mechanism of the 
placebo analgesia. 
 
7.2 Methods 
 
In order to make comparisons of the placebo effect in FM, OA and 
RA, three investigators created databases of each disease separately 
(Xi Chen, FM; Kun Zou, OA; Natasya Abdullah, RA) Treatments that 
have been studied in RCTs in two or all three of these conditions were 
then selected.  The effect size of placebo was then compared 
between the 3 conditions for each treatment. Four types of treatments 
(magnetic treatment, homeopathy, NSAIDs, and acupuncture) were 
found in common among the three diseases. I chose magnetic 
treatment and homeopathy in my study.  
 
7.3 Magnetic field placebo in FM, OA and RA 
 
Magnetic field was one of the treatments that have been studied in 
placebo-controlled RCTs in FM, OA and RA.  There were 4 placebo-
controlled trials of magnetic field in FM, 15 trials in OA and 2 trials in 
RA. Study characteristics are in Table 7-1. Pain reduction was 
measure in the RCTs in all three conditions (Table 7-2). 
Table 7-1 Study characteristics 
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Features FM OA RA 
No. of total participants 156 659 134 
No. of placebo treatment participants  77 310 96 
Mean age, yr in placebo group 46.7 50.2 61.7 
Women% in placebo group 91.3% 89.7% 78.1% 
 
Table 7-2 Pain reduction by placebo in three diseases 
Disease No. of 
trials 
ES (95%CI) Heterogeneity P publication bias 
FM 4 0.30 (-0.02, 
0.62) 
0%, p=0.94 0.01 
OA 15 0.71 (0.31, 
1.11) 
85.4%, p<0.05 0.29 
RA 2 0.39 (0.10, 
0.68) 
N/A N/A 
 
Meta-analysis has shown that sham magnetic field device (placebo) 
was effective for OA and RA, but not for FM. The placebo effect in 
these trials was greatest in OA, with a mean effect size that was more 
than twice that in the other 2 conditions. The placebo response in RA 
was next in magnitude, and the lowest effect size was in FM (Figure 
7-1). 
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Figure 7-1 Cross disease comparison (magnetic field) 
 
7.2 Homeopathy in FM and RA 
 
Homeopathy is a system of alternative medicine, based on the  
doctrine of ³like cures like´, according to which a substance that 
causes the symptoms of a disease in a healthy person will cure similar 
symptoms in a sick person (Evans et al., 2013). However, one major 
difference with homeopathic medicines is that substances are used 
in ultra high dilutions, which makes them non-toxic. It is widely held, 
however, that there is little if any scientific support for this hypothesis 
(Belfer et al., 2013).  As yet, science has not been able to explain the 
mechanism of action of ultra high dilutions in the body, but laboratory 
experiments have repeatedly demonstrated that homoeopathically 
prepared substances cause biological effects. 
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Based on the fact that the highly diluted homeopathy remedies barely 
contain any ³real medicine´, the therapeutic effect is largely 
contributed by the contextual factors, which are not the result of the 
active components of the treatment but are inherent within the 
WUHDWPHQW ³SDFNDJH´ (Steinsbekk et al., 2007). Therefore, 
homeopathy is in fact a placebo on its own with large contextual 
factors in delivery. In this review, only trials with homeopathy 
consultation were included to understand how the context of 
³WUHDWPHQW SDFNDJH´ LQIOXHQFHV chronic pain conditions. Data were 
taken from the homeopathy treatment groups.  
 
Two homeopathy trials were found in FM and another two trials were 
found in RA. Study characteristics are in Table 7-3. Homeopathy 
(placebo) was neither effective in FM, nor in RA for pain outcome 
(Figure 7-2). 
 
Table 7-3 Homeopathy study characteristics 
Features FM RA 
No. of total participants  109 142 
No. of placebo treated participants  53 128 
Mean age, yr in placebo group 46.5 63.4 
Women% in placebo group 96.4% 77.7% 
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Figure 7-2 Placebo effect for pain due to FM and RA in homeopathy 
trials 
 
7.4 Discussion  
 
The placebo effect in the three conditions varied, depending on the 
type of placebos. For example, magnetic field placebo works for OA 
and RA but not FM, suggesting that placebo may only work for 
mildly/partially central-sensitised pain.    
FM 
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The three selected pain conditions are all common rheumatoid 
diseases. Chronic pain is a feature of all three, but with different 
mechanisms.  
 
FM is the prototypical non-inflammatory chronic pain syndrome. 
Abnormalities in pain perception have been identified by quantitative 
sensory testing methods. Compared to healthy controls, FM patients 
have notably lower pressure pain thresholds (Hudson et al., 2003). 
Partly due to specific defects such as loss of descending analgesic 
activity and central sensitization, the diffuse hyperalgesic state of 
central augmentation of pain processing has been often identified 
(Gracely et al., 2002). 
 
In contrast to FM, RA is a typical systemic inflammatory disease. The 
inflammation contributes to the chronic pain in RA. However, 
inflammation may not be the only pain-causing factor. Some patients 
do not get improvement in pain reduction despite treatment with anti-
inflammatory drugs (Rupp et al., 2006). The central pain-processing 
mechanisms have also been examined. Studies that utilized 
dolermetry to assess pain thresholds suggest that RA patients have 
higher pain sensitivity than healthy control at both joint and non-joint 
sites (Rupp et al., 2006, Wolfe and Michaud, 2007).  
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OA is a common degenerative joint disease. Damage to cartilage and 
bone is the main character of this condition. Because of the chronic 
pain, many individuals with OA suffer from significant disability and 
health care costs (Lawrence et al., 2008). There is a lot of debate on 
the pain mechanism of OA. The association between pain intensity 
and peripheral joint damage is poor at a population level (Bedson and 
Croft, 2008) but strong within individuals (Neogi et al., 2009). Studies 
have shown that, OA pain which is considered peripheral driven, 
historically, may also be modulated via widespread mechanism 
controlled by the central nervous system. A recent systematic review 
has demonstrated that people with OA have lower pressure pain 
threshold than non-OA controls at the disease joint site, distal and 
remote areas (Suokas et al., 2012).  
 
Many epidemiological studies also observe that people with OA are 
more likely to develop pain elsewhere at the late stage of the disease 
(Ingham et al., 2011), and about 12.1% people still suffer from chronic 
pain after the total joint replacement (Nikolajsen et al., 2006). These 
suggest that pain in OA also has some central components, although 
it may not similar as pain in FM.    
 
It has been stated that the placebo analgesia is predominantly 
mediated by enhancement of descending inhibitory systems. Three 
principal pharmacologic mediators have been suggested, namely, 
high levels of endogenous opioids, dopamine release, and low levels 
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of cholecystokinin (Abhishek and Doherty, 2013). The role of 
endogenous opioids in placebo analgesia has been proved in a few 
studies.  According to Lipman, the cerebrospinal fluid concentration 
of endogenous opioids is higher in chronic pain patients who 
responded to the placebo administration than the ones that didn¶t 
respond (Lipman et al., 1990). The fact that the placebo response 
induced by verbal suggestion could be blocked by naloxone (an 
opiate antagonist) also confirms the role of opioids in mediating 
placebo analgesia (Amanzio and Benedetti, 1999). 
 
The opioid receptors are widely and differentially expressed in central 
nervous systems (Abbadie et al., 2000, Mansour et al., 1995). The ȝ-
opioid receptors, in particular are widely distributed throughout the 
forebrain, midbrain, and hindbrain. Its distribution corresponds with 
its role in pain perception and sensorimotor integration (Mansour et 
al., 1988).  Conversely, moderate amounts of Ʈ-opioid receptors 
have been found in many brain areas (Mansour et al., 1988). In the 
peripheral nervous systems, the opioid receptor expression was also 
found (Bagnol et al., 1997, Gray et al., 2005, Holzer, 2004). 
Peripheral opioid receptor-mediated analgesia has also been well 
studied in clinical trials. According to Tegeder, administration of the 
peripherally restricted opioid agonists (M6G) could reduce 
hyperalgesia induced by peripheral actions (Tegeder et al., 2003). 
Topical administration of opioid also achieved effective pain reduction 
in the treatment of painful skin ulcers (Twillman et al., 1999). The 
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expression of opioid receptors in both central and peripheral nervous 
systems potentially explained how placebo-induced endogenous 
opioids achieve analgesia in both central and peripheral driven painful 
conditions.   
 
7.5 Caveats and future work 
 
This is an attempt to understand the impact of pain mechanism on 
the placebo response. Three pain models were used to compare the 
placebo effect in this study. However, the study carried a few caveats. 
First of all, the small number of available studies for the comparison 
is the biggest caveat. The evidence has shown that different pain 
mechanisms may have an impact on the magnitude of the placebo 
effect. But the result is not consistent. The small number of available 
trials may be the main reason for the inconsistent results. Also 
because of the small trial number, it was impossible to do subgroup 
analysis. Secondly, the magnetic and homeopathy treatments 
chosen for this comparison did not have classic placebo. Both 
treatments were complementary and alternative medicine and the 
design of placebo was not easy. Thirdly, comparison was only done 
on pain reduction due to available data. Pain was a shared outcome 
by all the three conditions. However, it is the only shared outcome 
that has been reported in the included trials. Quality of life and overall 
improvement were also considered as shared outcomes for 
comparison, but no data were extracted from the available trials.   
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Future research needs to include more trials from each of the three 
conditions by increasing the type of treatment. Association of the 
placebo effect with certain type pain mechanism needs to be further 
clarified.  
 
7.6 Brief summary 
 
 
Attempt was made to compare the placebo effect in three diseases, 
OA, RA and FM. Two commonly used treatments among the three 
diseases magnetic therapy and homeopathy were chosen to make 
the comparison. The result was tentative which may be due to small 
sample size and practicalities of using placebo in these trials. 
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Chapter 8 General Discussion  
 
8.1 Summary of study findings 
 
FM is a common condition in the general population that causes 
multiple regional pain, fatigue and chronic disability. The mechanism 
of pain is predominantly central and strongly associates with non-
restorative sleep and lack of delta sleep. Many studies have 
investigated different treatments for FM, which provides an 
opportunity to systematically review the placebo effect in RCTs 
undertaken in FM. Over two hundred placebo-controlled trials were 
found in the literature search. A wide range of different treatments 
were studied in these trials, including drugs, physical interventions 
such as exercise and balneotherapy, psychological treatments such 
as CBT, and complementary therapies such as homeopathy and 
acupuncture.  Some trials used placebo as their study control while 
others used an untreated group as control. This permits an 
investigation of the placebo effect and its determinants in FM. This 
study has yielded three key findings. Firstly, participants treated by 
placebo obtain significant improvements in all the main outcome 
measures such as pain, fatigue, sleeping quality, functionality and 
overall wellbeing. Secondly, these effects are superior to any 
changes observed in untreated control groups. Thirdly, the main 
determinants that increase the magnitude of this placebo effect in FM 
are: a higher effect size of the active treatment, greater symptom 
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severity at baseline, being male, older age, and having a shorter 
duration of FM.   
 
8.2 Placebo effect in FM 
 
The first objective of the study is to determine whether placebo is 
effective in FM. Since the power of the placebo response was first 
highlighted by Beecher, (Beecher, 1955), the debate as to whether 
the placebo effect exists never stopped. Many studies suggest that 
the observed beneficial effects from placebo could be explained by 
factors such as the natural remission of disease and regression to the 
mean. However, the comparison between the placebo group and 
untreated control and waiting list control in the present review strongly 
supports the existence of the placebo effect in FM.  A similar finding 
was also observed by Zhang, et al, (2008) in OA, where a true positive 
placebo effect (ES, 0.51, 95% CI 0.46 to 0.55) was found, compared 
to untreated group. Overall, the pain reduction caused by placebo in 
OA is greater than that observed in FM, which suggests that different 
mechanisms of pain may be amenable to placebo.   
 
There are several possible explanations of why placebo could benefit 
FM patients. Firstly, the patients¶ expectation of clinical benefits may 
play a critical role in the placebo effect (Benedetti, 2008). Different 
studies have shown that the administration of placebo could modulate 
patients¶ pain perception and the placebo response was dependent 
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on expectation (Price et al., 1999, Benedetti et al., 2003). In 
Benedetti¶s experiment, two groups of participants were 
administrated a pharmacological preconditioning with ketorolac for 
two days. In the third day, ketorolac was replaced by placebo for both 
groups but one group received verbal suggestion of analgesia and 
the other group received verbal suggestion of hyperalgesia.  The 
positive verbal instructions induced strong placebo analgesia but the 
negative verbal instructions produced hyperalgesia. It demonstrated 
that placebo analgesia depends on patients¶ expectation of pain 
reduction (Benedetti et al., 2003). In the clinical trial setting, FM 
patients were expecting to be treated. Although they had been 
informed of the chance of getting placebo before getting into the trials, 
the expectation of getting the real treatment and improvement of the 
symptoms might still trigger the placebo response.  
 
Secondly, the contextual meaning of the treatment could be a factor 
to produce the placebo response. When patients were enrolled in a 
trial, they were assessed by doctors and they were fully aware of the 
whole treatment process. Nelson found that any medical treatment 
has two components, the specific effects of the treatment and the 
knowledge that the treatment is being performed. In his study, 
patients who were administrated with analgesics openly had larger 
improvement than patients who had hidden administration of the 
drugs (Nelson et al., 2010). It proves that patientV¶ knowledge that the 
therapy was being performed can bring clinical benefits.  
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Thirdly, certain brain areas and specific neural systems might have 
been involved in the placebo effect. Neuroimaging has provided 
evidence that the endogenous opioid system is central to mediating 
placebo effects on pain,  and placebo analgesia is associated with a 
number of brain regions, including prefrontal, limbic, and brainstem 
regions (Bennett et al., 2003, Patkar et al., 2007). FM pain is a result 
of augmentation of sensory input that is mediated by the central 
nervous system and also peripheral sensitisation with reduced 
efficiency of descending inhibitory systems (Nielsen and Henriksson, 
2007). The placebo might have improved FM symptoms by mediating 
the activity of brain and neural systems.  
 
8.3 Determinants of the placebo effect  
 
The second objective of the study is to find possible determinants of 
the placebo effect in FM. Several factors have been investigated, 
among which patients¶ gender and age, treatment effect size, 
baseline severity and duration of disease were found to have potential 
influences on the magnitude of placebo effect.  
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8.3.1 Effect size of treatment  
 
The effect size of the placebo increased in line with the effect size of 
the active treatment. This supports the theory that the magnitude of 
the placebo effect is largely determined by the expectation of the 
patients. Vase also agreed on this finding in tKHLU³SODFHERDQDOJHVLD´
study. In this study, the placebo for drugs had larger effect size than 
that for the non-drug treatments (Vase, 2002). In the present study, 
the placebo effect size for analgesics was 0.37 (95%CI 0.19 to 0.50), 
antidepressants, 0.57 (95%CI 0.52 to 0.63), muscle relaxant, 0.55 
(95%CI 0.12 to 1.00), and hypnotics, 0.51 (95%CI 0.37 to 0.66). While, 
the placebo effect size for acupuncture was 0.28 (95%CI -0.04 to 0.59) 
and that for electromagnetic therapy was 0.30 (95%CI -0.02 to 0.62). 
It indicates that the patient expectation for non-pharmacological 
treatments and alternative medicines may be less than that for 
pharmacological treatments in FM. When patients know that they 
have been involved in a trial with stronger treatment, their expectation 
is enhanced. Consequently, the placebo response in such trials 
becomes higher. The result was also proven in a coffee study. 
Participants were all given decaffeinated coffee but the ones who 
were told that they would all receive regular coffee had a greater 
increase in alertness and heart-rate than the ones who were told that 
they would receive either regular or decaffeinated coffee (Kirsch and 
Weixel, 1988).   
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8.3.2 Baseline severity and duration of disease 
 
Baseline pain severity has been considered as a predictor for placebo 
response. A positive association between baseline pain and the 
placebo effect was found in OA (Zhang, et al, 2008). According to 
Goetz, Parkinson¶s disease patients with higher baseline function 
were more likely to have higher placebo effect (Goetz et al., 2008). In 
this study, we also found positive association between the two.  
However, the duration of FM was found to have a negative 
association with the placebo effect. Patients who suffered from FM 
for longer period of time had smaller placebo effect. In fact, it has 
been studied that early intervention to FM could promise a higher 
chance of good prognosis (Goetz et al., 2008), which means the 
longer the patients live with FM, the harder it becomes to treat the 
disease, including by placebo. Also patients with longer experience 
of FM have better understanding that treatments may have limited 
effect on the disease. Therefore, their expectation becomes lower.  
 
8.3.3 Gender 
 
Gender is a proven determinant of the placebo response (Hauser et 
al., 2012a). The male gender has been suggested to be better 
placebo responder in a few studies. In a placebo analgesia study, 
male participants responded to the manipulation of the expectancies 
through pain information during ischemic pain, but the female 
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participants did not (Flaten et al., 2006). In a conditioning study that 
employed a motion-sickness paradigm, men showed a greater 
reduction in rotation tolerance and responded more strongly to 
rotation and to suggestions than women (Enck et al., 2008). Different 
results were also found in the literature. According to Averbuch and 
Katzper, no gender difference was found in response to placebo (De 
Craen et al., 1999a). The present study used subgroup analysis and 
found that the placebo effect decreased in women. In other words, 
men are more likely to respond to placebo. This finding is consistent 
with the fact that women are more likely to have FM and other chronic 
pain than men. Women also reported longer duration of symptoms 
than men (Munguia-Izquierdo and Legaz-Arrese, 2008, Tomas-Carus 
et al., 2007a). The management of these types of pain is more 
challenging in women.  
 
One possible explanation is that women perceive disease differently 
from men. Women have significantly greater self-reported symptom 
awareness than men (Vlahiotis et al., 2010). Because of greater 
selective attention to their bodies and an increased attribution of 
bodily sensations to physical illness, women perceive an excess of 
symptoms compared with men (Da Costa et al., 2005).  
 
Another reason why men are more likely to respond to placebo is that 
men are better responders to treatments in general, considering the 
placebo was administrated to FM patients as a treatment in the trials. 
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According to Mathai, the likelihood of response to tadalafil in 
pulmonary arterial hypertension patients is higher in men than women 
(Ang et al., 2010). In Achilles tendinopathy patients, eccentric training, 
an exercise that has been proven to be very effective in treating pain 
in the middle of the Achilles tendon, resulted in significantly larger 
pain reduction in men than women (Van Koulil et al., 2010). The same 
result is also found in a growth hormone treatment study. In the study, 
boys with growth hormone deficiency, or multiple pituitary hormone 
deficiency had significantly better response to growth hormone 
treatment (Edinger et al., 2005b).    
 
The role of personality trait in placebo response has been studied. 
High dispositional optimism and low state anxiety were found to be 
significant predictors of placebo response (Carleton et al., 2011). 
According to Parmelee (2009), female gender is associated with 
greater psychological distress and that makes women less likely to 
respond to placebo. Novelty seeking personality trait is another 
predictor of placebo response (Carleton et al., 2011), and it is more 
prevalent in men (Ali et al., 2009). The association between gender 
and personality traits also partially explains why men are better 
placebo responders.  
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8.3.4 Age  
 
The present study found that the placebo effect increased with age. 
A few other studies also found that the elderly people had a significant 
response to placebo. For example, according to Alexopoulos, more 
than half of elderly depression patients showed at least 25% 
improvement by taking placebo (Alexopoulos et al., 2007). In 
Parkinson¶s disease studies, older individuals also showed a 
significant response to placebo (Goetz et al., 2008).  This could be 
explained by the fact that people of different ages have difference 
perception of disease. Although prevalence of FM goes up with age, 
older people report less severe symptoms. They are more likely to 
regard pain as part of the aging process and cope with it, (Cronan et 
al., 2002). Another possible explanation is that the older patients had 
higher treatment expectation. As Lewin has argued, higher treatment 
expectation is linked to better treatment response, (Kiyak, 2009). Best 
of our knowledge, there is no other study that has confirmed either 
positive or negative relationship between patient¶s age and the 
placebo effect in FM. Whether this age-related placebo effect in FM 
is related to the experience, social ability and other contextual factors 
deserves further investigation.  
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8.3.5 Other factors 
 
Industry funded trials had larger placebo effect (ES, 0.54, 95%CI 0.50 
to 0.59) than non-industry funded trials (ES, 0.41, 95%CI 0.17 to 0.64). 
In general, industry-funded trials tend to have more funding, and they 
often come with a new drug or new therapy. Drugs that tested in 
industry funded trials tend to have larger effect size than the same 
drugs in non-industrial funded trials (Finckh et al., 2005). This might 
enhance the contextual effect in the trial setting and bring up the 
placebo effect. 
 
Noticeably, the trials that recruited the participants via doctor¶s 
referral (ES, 0.56, 95%CI 0.51 to 0.61) had larger placebo effect than 
the ones that recruited the participants via advertisements (ES, 0.10, 
95%CI -0.18 to 0.37). As suggested by Kaptchuk, a warm 
consultation by a physician results in a larger placebo response 
(Kaptchuk et al., 2008b). In his IBS study, higher percent of patients 
who received sham acupuncture treatment with good patient-
practitioner interaction (62%) reported more pain relief than patients 
who also received sham acupuncture but with limited interaction with 
the practitioners (44%) (Kaptchuk et al., 2008b). It indicates that 
doctors¶ involvement had more weight to the effect size of the placebo. 
Studies have shown that the doctors¶ confidence, willingness to 
monitor the progress, the certainty of the diagnosis, and good outlook 
of the treatment results are all proven to be positive elements of how 
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doctors¶ evolvement can enhance the placebo response (Thomas, 
1987, Thomas, 1994, Gracely et al., 1985).   
 
Other factors have also been analysed as potential determinants of 
the placebo effect, such as blinding, route of delivery, length of 
treatment period, age of the treatment since it was first developed 
(based on the first publication), and the change of getting placebo. 
Blinding and concealment has been proven to have an impact on the 
treatment response, as in a post-operative analgesia study, hidden 
administration of parenteral morphine induced lower onset of pain 
relief than open administration of the same drug (Colloca et al., 2004). 
In general, more invasive way of drug delivery and higher frequency 
of drug administration are associated with higher placebo response 
(Zhang, et al., 2008). However, in this review, no clear tendency was 
found. It might be that the placebo effect in FM is not influenced by 
these factors or the available data are not sufficient to detect any 
tendency.  
 
Study quality was initially considered as a possible determinant of 
placebo effect. However, most placebo controlled trials had very good 
mark in the Jadad score. This made the subgroup analyses according 
to different quality scores difficult.  Further study using another quality 
indicator is warranted.   
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8.4 Is CAM just placebo˛ 
 
In this review, a few types of complementary and alternative 
medicines (CAM) were included. There are a lot of debates on 
whether CAM is just placebo. In fact, the answer depends on the 
specific type of CAM. Acupuncture is a typical CAM that has been 
used to treat FM. The results showed that acupuncture was effective 
in pain reduction and other FM symptoms management, and so was 
the sham acupuncture. According to Vickers, the therapeutic effect of 
acupuncture is not just placebo effect. In his systematic review of 
acupuncture for chronic pain, he found that acupuncture was an 
effective treatment for chronic pain and he also found significant 
difference between true and sham acupuncture. However, the 
difference was relatively modest. It suggested that acupuncture was 
more than a placebo but carried a large proportion of placebo effect 
(Vickers et al., 2012).  Homeopathy was another type of CAM in this 
review. The mechanism of the action of the ultra-high dilutions has 
not been scientifically explained. Based on the fact that homeopathy 
remedies barely contain any ³real medicine´ and the therapeutic 
effect is largely contributed by the contextual factor, it was regarded 
as placebo.  
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8.5 Applications of study findings 
 
The confirmation of placebo effect in this study can shed some light 
on clinical practise. Although the use of placebo as a treatment should 
be avoided (Wang et al., 2010a), good physicians should harness the 
placebo effect to maximise the benefits to their patients (Wigers et al., 
1996). Because the placebo effect consists of contextual effect which 
is largely derived from the physician-patient interaction (Alfano et al., 
2001), physicians should always maximise this interaction to enhance 
the treatment benefits.  
 
 
The study finding can also inform the future clinical trial design. Since 
the double-blind, randomised controlled trial has become the ³gold 
standard´ of clinical research, many researchers presuppose that 
effectiveness can only be granted if a treatment demonstrates an 
additional/specific effect over placebo (Kravitz et al., 2006). As being 
proved that the all treatments to FM carry certain proportion of 
placebo effect, it¶s no longer a valid presupposition that only a specific 
effect over placebo effect are worth looking for. In order to be aware 
of this placebo trap, future clinical trials should diversify research 
strategies to use multiple methods, such as randomised comparison 
against waiting list or usual care.  This type of comparison enables 
the researchers to quantify the overall benefit from the treatment.  
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8.6 Study caveats 
 
This study has a number of caveats. Firstly, the included trials may 
not cover all eligible trials in FM, especially those unpublished. Unlike 
the systematic review of placebo in OA, the number of FM RCTs was 
relatively small. Furthermore, many included trials did not present 
their result in numerical data and could not be used for meta-analysis. 
Although language was not restricted in the literature search, only a 
few non-English publications were found and none of these were 
included in meta-analysis because of the lack of numerical data. Like 
many other meta-analysis, we had to analyse the data at study-level, 
many determinants at individual patient level could not be 
characterised. 
 
Secondly, inclusion of many disparate treatments and their placebo 
in this review resulted in high heterogeneity for the placebo effect. 
Although we carefully considered the reasons for marked 
heterogeneity and undertook a number of subgroup analyses to 
identify the reasons for the heterogeneity, we still failed to identify the 
reasons of heterogeneity for some subgroups and a random effects 
model had therefore to be used to give an overall estimate. 
 
Thirdly, in order to prove the placebo effect in FM, it would be ideal to 
directly compare changes in a placebo treated group and an 
untreated control group within the same study. The placebo effect 
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was mainly determined as the difference between baseline and 
endpoint, rather than the difference in benefit between placebo and 
untreated groups. Only one trial with a three arm study design 
provided this comparison and unfortunately it had a small sample size 
and a limited number of outcome measures.  
 
Fourthly, the influence of gender on the magnitude of the placebo 
effect would best be studied by comparison between separate large 
groups of men and women who receive placebo. However, no trials 
separately reported outcomes according to gender. Instead, the 
percentage of women in the trials was used as an indirect way of 
determining a gender difference in placebo response.  
 
Furthermore, there was no untreated control group in the analysis for 
the nocebo effects.  The risk of the unwanted effects from the placebo 
group cannot therefore be separated from those from the FM 
symptoms or the effects caused by the factors other than placebo.  
 
8.7 Future work 
 
In future research, studies should focus on three aspects of the 
placebo effect in FM to further extend the knowledge from this 
systematic review. Firstly, determinants of the placebo effects should 
be investigated further at the patient level. Secondly, proportion of the 
placebo effect within each treatment need to be calculated. Being 
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able to understand the certain proportion of placebo effect that one 
treatment carries can provide better guidance to the design of new 
trials on the treatment. Thirdly, nocebo effect requires more research 
in the context of the comparison with the background risk of the 
unwanted events in the population, or an untreated control in trials.  
 
8.8 Overall conclusion of the study 
 
In conclusion, the placebo has been proven to be effective in FM. It 
reduces pain, fatigue and depression, improves non-restorative sleep 
and overall quality of life. The effect size of placebo is significantly 
influence by the effect size of the treatment. Men are more responsive 
to placebo, so does older age.  In contrast, the longer duration of 
disease is, the more difficult to demonstrate the placebo effect. Not 
only can placebo be effective as a treatment in FM but it may also 
cause some side effects, though less than those from the active study 
medication.  The placebo effect in FM may be smaller than that in OA 
or RA.  
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Appendix 1 Searching strategy 
  
Medline OVID 1948-present 
 
1. exp Meta-Analysis/ 
2. systematic review.mp. 
3. quantitative review.mp. 
4. quantitative overview.mp. 
5. statistical pool.mp. 
6. 1 or 2 or 3 or 4 or 5 
7. exp Randomized Controlled Trial/ 
8. exp Clinical Trial/ 
9. exp Double-Blind Method/ 
10. exp Single-Blind Method/ 
11. Comparative Study/ 
12. 7 or 8 or 9 or 10 or 11 
13. exp Fibromyalgia/ 
14. fibromyalgia syndrome.mp. 
15. Chronic widespread pain.mp. 
16. Fibrositis.mp. or Fibromyalgia/ 
17. 13 or 14 or 15 or 16 
18. 12 and 17 
19. 6 and 17 
20. 18 or 19 
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Appendix 2 Data extraction form 
 
Randomised controlled trial 
 
General 
Trial ID             Category        
Author(s)         
Disease            
Year of publication         Country         
Setting   Community     GP    
Hospital  
Study design       parallel     cross-
over  
Source              
Funding body       Industry (fully  partially  unclear )      Non-industry         
Unknown  
 
4XDOLW\RIWULDO-DGDG¶VFKHFNOLVW7RWDOVFRUH      
Question Yes No Unknown/NA 
6. Was the study described as randomised (This 
includes the use of words such as randomly, 
random, and randomisation)? 
1 
0 
 
7. Was the method of random allocation appropriate 
(eg, table of random numbers, computer 
generated, etc)? 
1 -
1 
0 
8. Was the study described as double blind? 1 
0 
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9. Was the method of double blind appropriate (eg, 
identical placebo, active placebo, dummy, etc)? 
1 -
1 
0 
10. Was there a description of withdrawal and drop-
outs? 
1 
0 
 
 
Further quality assessment 
 Random 
number 
Allocation 
concealment 
Blind 
care 
provider 
Blind 
patient 
Blind 
assessor 
Intention 
to treat 
analysis 
Yes       
No       
Unknown       
 
Details about the trial 
Diagnostic criteria:       Existing therapy   Continued   Stopped  
Unknown                        
Proportion/eligible       Primary outcome       
 
Demographic info 
Intervention (route, 
dosage and treatment 
period) 
Number of 
patients 
Number of 
withdrawals 
Age 
( mean±SD) 
Female% 
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Observational period:       
Outcome Pain       
Group (intervention) Baseline Endpoint Change 
Mean SD Mean SD Mean SD 
                                          
                                          
                                          
                                          
 
Outcome Fatigue       
Group (intervention) Baseline Endpoint Change 
Mean SD Mean SD Mean SD 
                                          
                                          
                                          
                                          
 
Outcome Function       
Group (intervention) Baseline Endpoint Change 
Mean SD Mean SD Mean SD 
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Outcome Sleep       
Group (intervention) Baseline Endpoint Change 
Mean SD Mean SD Mean SD 
                                          
                                          
                                          
                                          
 
Outcome Quality of Life (QoL)       
Group (intervention) Baseline Endpoint Change 
Mean SD Mean SD Mean SD 
                                          
                                          
                                          
                                          
 
Outcome other 1:       
Group (intervention) Baseline Endpoint Change 
Mean SD Mean SD Mean SD 
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Outcome other 2:       
Group (intervention) Baseline Endpoint Change 
Mean SD Mean SD Mean SD 
                                          
                                          
                                          
                                          
 
Adverse event (s) 
Side-effect a/n1 b/n2 
                  
                  
                  
 
 
 
 
 
 
Comments:            
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Appendix 3 Full report of study characteristics   
 
Category Trial Country Funding body Jadad score Treatment Control Age (E) Age (C) 
Self-management 1. (Cedraschi et 
al., 2004)  
Switzerland Non-industry 3 Self-management Waiting list 48.9 49.8 
Self-management 2. (Hsu et al., 
2010) 
USA Non-industry 3 Self-management Waiting list Not 
reported 
Not reported 
Self-management 3. (Williams et al., 
2010) 
USA Non-industry 3 Self-management Usual care 50.17 50.75 
Patient education 4. (Sukenik et al., 
1999a) 
Spain Unknown 3 Patient education Usual care 39.2 42.3 
Patient education 5. (Stuifbergen et 
al., 2010) 
USA Non-industry 3 Patient education Usual care Not 
reported 
Not reported 
Exercise  6. (Mccarney et al., 
2007) 
USA Non-industry 3 Qigong Usual care Not 
reported 
Not reported 
Exercise  7. (Verhagen et al., 
2007) 
Spain Non-industry 3 Multidisciplinary 
rehabilitation 
Usual care 50 51.4 
Exercise  8. (Carson et al., 
2010) 
USA Unknown 3 Exercise Waiting list 51.4 55.8 
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Exercise  9. (Stigler, 1997) Spain Unknown 3 Exercise Usual care 54.07 55.06 
Exercise  10. (Da Costa et al., 
2005) 
Canada Unknown 3 Exercise Usual care 49.2 52.3 
Exercise  11. (Fontaine et al., 
2010) 
USA Non-industry 2 Exercise Usual care 48.5 47.8 
Exercise  12. Garbonell-
Baeza 2010 
Spain Unknown 1 Dance Waiting list 54.2 51.4 
Exercise  13. (Gowans et al., 
2001) 
Canada Unknown 3 Exercise Usual care Not 
reported 
Not reported 
Exercise  14. (Gusi et al., 
2006) 
Spain Non-industry 3 Exercise Usual care 51 51 
Exercise  15. (Haak and Scott, 
2008) 
Sweden Unknown 3 Qigong Waiting list 54 53.4 
Exercise  16. Hammond 2005,  UK Unknown 3 Exercise Usual care 48.36 48.73 
Exercise  17. (King et al., 
2002) 
Canada Non-industry 3 Exercise Waiting list 45.2 47.3 
Exercise  18. (Kingsley et al., 
2005) 
USA Non-industry 3 Exercise Waiting list 45 47 
Exercise  19. (Lemstra and 
Olszynski, 2005)  
Canada Unknown 3 Multidisciplinary 
rehabilitation 
Usual care 49.7 49.11 
Exercise  20. (Martin et al., 
1996)  
Canada Non-industry 3 Exercise Usual care 43.9 45.7 
 202 
 
Exercise  21. (Munguia-
Izquierdo and 
Legaz-Arrese, 
2008) 
Spain Unknown 3 Exercise Usual care 50 46 
Exercise  22. (White et al., 
1999a) 
Spain Unknown 3 Titling whole body 
vabration 
Usual care 52.4 53 
Exercise  23. (Sanudo et al., 
2011) 
Spain Non-industry 3 Exercise Usual care 55.48 56.15 
Exercise  24. (Tomas-Carus 
et al., 2007b) 
Finland Unknown 3 Exercise Usual care 51 51 
Exercise  25. (Tomas-Carus 
et al., 2007a) 
Portugal Unknown 2 Exercise Usual care 51 51 
Exercise  26. (Tomas-Carus 
et al., 2008) 
Spain Unknown 3 Exercise Usual care 50.7 50.9 
Exercise  27. (Tomas-Carus 
et al., 2009) 
Spain Unknown 3 Exercise Usual care 50.7 50.9 
Exercise  28. (Valkeinen et al., 
2008) 
Finland Non-industry 3 Exercise Usual care 59 58 
Exercise  29. (Van Santen et 
al., 2002) 
Netherland Non-industry 3 Exercise Usual care 46.2 42.8 
Exercise  30. (Wang et al., 
2010a) 
USA Unknown 3 Tai Chi Usual care 49.7 50.5 
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Exercise  31. (Wigers et al., 
1996) 
Norway Non-industry 3 Exercise Usual care 43 46 
Physical 
treatment 
32. (Alfano et al., 
2001) 
USA Unknown 4 Magnetic field Sham 
treatment 
44 44.8 
Physical 
treatment 
33. (Almeida et al., 
2003) 
Brazil Unknown 4 Ultrasound and current Sham 
treatment 
56 57 
Physical 
treatment 
34. (Babu et al., 
2007) 
India Unknown 5 EMG Sham 
treatment 
43.2 35.3 
Physical 
treatment 
35. (Bach and 
Clement, 2007) 
Germany Unknown 3 Farabloc Sham 
treatment 
49.02 48.08 
Physical 
treatment 
36. (Colbert et al., 
1999) 
USA Partially industry 5 Magnetic field Sham 
treatment 
51.15 48.17 
Physical 
treatment 
37. (Enck et al., 
2008) 
Turkey Unknown 2 Laser Sham 
treatment 
Not 
reported 
Not reported 
Physical 
treatment 
38. (Hauser et al., 
2012a) 
USA Non-industry 5 Electrostimulation Sham 
treatment 
51.3 54 
Physical 
treatment 
39. (Kravitz et al., 
2006) 
USA Non-industry 5 Neurofeedback Sham 
treatment 
45.9 48.1 
Physical 
treatment 
40. (Nelson et al., 
2010) 
USA Non-industry 5 Neurofeedback Sham 
treatment 
51.6 52 
Physical 
treatment 
41. (Passard et al., 
2007b) 
France Unknown 5 Magnetic field Sham 
treatment 
52.6 55.3 
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Physical 
treatment 
42. (Roizenblatt et 
al., 2007) 
Brazil Non-industry 4 Current stimulation Sham 
treatment 
54.2 50.8 
Physical 
treatment 
43. (Alghalyini, 
2008) 
USA Unknown 4 Magnetic field Sham 
treatment 
54.2 51.67 
Physical 
treatment 
44. (Sutbeyaz et al., 
2009b) 
Turkey Unknown 5 Magnetic field Sham 
treatment 
42.96 40.89 
CBT 45. (Goetz et al., 
2008) 
Spain Unknown 3 CBT Usual care 46.35 47.04 
CBT 46. (Ang et al., 
2010) 
USA Unknown 3 CBT Usual care Not 
reported 
Not reported 
CBT 47. (Edinger et al., 
2005b) 
USA Unknown 3 CBT Usual care 50.1 48.3 
CBT 48. (Sephton et al., 
2007) 
USA Non-industry 3 Mindfulness-based stress 
reduction 
Waiting list 48.4 47.6 
CBT 49. (Van Koulil et 
al., 2010) 
Netherland Non-industry 3 Pain-persistence CBT Waiting list 41.1 40.9 
CBT  50. (Carleton et al., 
2011) 
Canada Unknown 5 Attention modification Sham 
treatment 
Not 
reported 
Not reported 
CBT  51. (Kool et al., 
2009) 
Germany Unknown 3 CBT Waiting list 53.4 52.3 
Acupuncture 52. (Deluze et al., 
1992) 
Switzerland Unknown 5 Acupuncture Sham 
treatment 
46.8 49 
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Acupuncture 53. (Pfingsten et al., 
2001) 
USA Unknown 3 Acupuncture Sham 
treatment 
46.1 48.1 
Acupuncture 54. (Martin et al., 
2006a) 
UK Unknown 3 Acupuncture Sham 
treatment 
51.7 47.9 
Balneotherapy 55. (Ardic et al., 
2007) 
Turkey Unknown 3 Thermal bathing Waiting list 43.5 48.8 
Balneotherapy 56. (Evcik et al., 
2002) 
Turkey Unknown 2 Thermal bathing Usual care 42 41.5 
Balneotherapy 57. (Fioravanti et al., 
2007) 
Italy Unknown 2 Mud pack+ bath Usual care 46.2 48.6 
Balneotherapy 58. (Fioravanti et al., 
2009) 
Italy Unknown 2 Phytothermotheray Usual care 53.2 48.62 
Balneotherapy 59. (Camerlain and 
Myhal, 2009) 
Netherland Unknown 3 SPA Usual care 48 47 
CAM 60. (Ali et al., 2009) USA Non-industry 5 Intravenous micronutrient 
therapy 
Placebo 51.7 50.7 
CAM 61. (Kiyak, 2009) Turkey Unknown 5 Wool Sham 
treatment 
37.4 37.4 
CAM 62. (Menzies et al., 
2006) 
USA Non-industry 2 Guided imagery Usual care Not 
reported 
Not reported 
Analgesics  63. (Arnold et al., 
2007) 
USA Partially industry 5 Gabapentin Placebo 49.2 47.3 
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Analgesics  64. (Mease et al., 
2008) 
USA Unknown 5 Pregabalin Placebo 50.9 49 
Analgesics  65. (Bennett et al., 
2003) 
USA Fully industry 5 Tramadol/Acetaminophen Placebo 49 51 
Analgesics  66. (Crofford et al., 
2005) 
USA Unknown 5 Pregabalin Placebo 48 49.7 
Analgesics  67. (Mease et al., 
2008) 
USA Unknown 5 Pregabalin Placebo 50.1 48.6 
Analgesics  68. (Berger et al., 
2007) 
Multi-
national 
Fully industry 5 Pregabalin Placebo 49.6 48.1 
Analgesics  69. (Skrabek et al., 
2008) 2008 
Canada Non-industry 5 Nabilone Placebo Not 
reported 
Not reported 
Analgesics  70. (Vaeroy et al., 
1989) 
Norway Unknown 5 Carisoprodol, paracetamol 
& caffeine 
Placebo 46 48.3 
Antidepressant  71. (Arnold et al., 
2002) 
USA Fully industry 3 Fluoxetine Placebo 46 46 
Antidepressant  72. (Arnold et al., 
2004) 
USA Fully industry 5 Duloxetine Placebo 49.9 48.3 
Antidepressant  73. (Arnold et al., 
2005) 
USA Fully industry 5 Duloxetine Placebo Not 
reported 
Not reported 
Antidepressant  74. (Arnold et al., 
2010b) 
USA Fully industry 5 Duloxetine Placebo 50.7 49.6 
 207 
 
Antidepressant  75. (Mccarney et al., 
2007) 
USA Fully industry 5 Milnacipran Placebo 49.1 48.7 
Antidepressant  76. (Arnold et al., 
2010a) 
USA Fully industry 5 Esreboxetine Placebo 49.2 50.1 
Antidepressant  77. (Arnold et al., 
2012) 
USA & 
Canada 
Fully industry 5 Esreboxetine Placebo 50.6 49.9 
Antidepressant  78. (Sukenik et al., 
1999b) 
Multi-
national 
Fully industry 5 Milnacipran Placebo 48.3 49.2 
Antidepressant  79. (Carette et al., 
1986) 
Canada Unknown 2 Amitriptyline Placebo 41.8 40.1 
Antidepressant  80. (Hadler, 2003) Canada Partially industry 5 Amitriptyline Placebo 44.1 47.1 
Antidepressant  81. (Russell et al., 
2008) 
Multi-
national 
Fully industry 3 Duloxetine Placebo 50.75 50.23 
Antidepressant  82. (Clauw et al., 
2008)  
USA Fully industry 5 Milnacpran Placebo 49.5 50.7 
Antidepressant  83. (Last and 
Adelaide, 2013) 
Switzerland, 
Czech 
Republic, 
Germany 
Fully industry 2 Terguride Placebo 48.5 49 
Antidepressant  84. (Farber et al., 
2000) 
Germany Fully industry 5 Tropisetron Placebo 50 48.5 
Antidepressant  85. (Benedetti et al., 
2007) 
USA Fully industry 5 Milnacipran Placebo 47.4 48 
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Antidepressant  86. (Burns et al., 
2005) 
Belgium Fully industry 5 Amitriptyline Placebo 46 46 
Antidepressant  87. (Enck et al., 
2008) 
Turkey Unknown 2 Amitriptyline Placebo 30.36 28.52 
Antidepressant  88. (Hannonen et 
al., 1998) 
Finland Unknown 5 Moclobemide Placebo 47.6 48.9 
Antidepressant  89. (Heymann et al., 
2001) 
Brazil Unknown 5 Amitriptyline Placebo 53.4 49.4 
Antidepressant  90. (Mease et al., 
2009) 
USA Fully industry 5 Milnacipran Placebo 49.9 49.4 
Antidepressant  91. (Norregaard et 
al., 1995) 
Denmark Fully industry 3 Citalopram Placebo 48 50 
Antidepressant  92. (Patkar et al., 
2007) 
USA Fully industry 5 Paroxetine Placebo 47.9 49.1 
Antidepressant  93. (Russell et al., 
2008) 
US & Puerto 
Rico 
Fully industry 3 Duloxetine Placebo 50.9 50.3 
Antidepressant  94. (Sorensen et al., 
1995) 
Germany Fully industry 4 Tropisetron Placebo 50 48.5 
Antidepressant  95. (Spath et al., 
2004) 
Germany Fully industry 4 Tropisetron Placebo 51.2 48.5 
Antidepressant  96. (Vergne-Salle et 
al., 2011) 
France Unknown 3 Dolasetron Placebo 49.1 51.3 
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Antidepressant  97. (Hawley and 
Wolfe, 1994) 
USA Fully industry 5 Fluoxetine Placebo 48 52.9 
Hyponotics 98. (Sicras-Mainar 
et al., 2009) 
USA Fully industry 5 Sodium oxybate Placebo 47.4 47.3 
Hyponotics 99. (Boonen et al., 
2005) 
USA Fully industry 5 Sodium oxybate Placebo 47 46.5 
Hyponotics 100. (Asbring and 
Narvanen, 2003) 
Multi-
national 
Unknown 5 Sodium oxybate Placebo 46.4 46.8 
Homeopath 101. (Bell et al., 
2004) 
USA Unknown 5 Homeopath Placebo 49.1 47.9 
Homeopath 102. (Relton et al., 
2009) 
UK Non-industry 3 Homeopath Usual care 43.9 47.2 
Hormone 103. (Bennett et al., 
1998) 
USA Fully industry 5 Growth hormone Placebo 47.9 46.5 
Hormone 104. (Finckh et al., 
2005) 
Swiss Non-industry 5 Dehydroepiandrosterone Placebo 59.2 58.7 
Alpha1-antitrypsin 105. (Russell et al., 
1999) 
Spain Fully industry 5 Alpha1-antitrypsin Placebo Not 
reported 
Not reported 
Anticholinesteras
e 
106. (Jones et al., 
2008) 
USA Non-industry 3 Pyridostigmine Placebo 49.31 49.78 
Muscle relaxant 107. (Briones-
Vozmediano et 
al., 2013) 
Canada Fully industry 5 Cyclobenzaprine Placebo 45.9 39.3 
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* Age (E), mean age of the experimental group; Age (C), mean age of the controlled group; CAM, complementary and alternative medicine; CBT, cognitive-
behavioural therapy; N/A, not applicable        
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Appendix 4 Publication bias 
 
 
Pain 
-1 0 1 2 
0.6 
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Sleep quality 
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Effect size 
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Fatigue 
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Effect size 
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Depression 
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0.00 
Effect size 
Standard error 
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Appendix 5 Common adverse effects by treatment  
Treatment Common AEs 
Nalilone Drowsiness 
Vertigo 
Euphoria 
Dry mouth 
Ataxia 
Visual Disturbance  
Concentration difficulties  
Sleep disturbance 
Dysphoria  
Hypotention 
Headache 
Nausea 
Amitriptyline Dizziness 
Sleep disturbance 
Drowsiness 
Dry mouth 
Blurred vision 
Constipation 
Fatigue  
Citalopram  Dizziness 
Sleep disturbance 
Drowsiness 
Dry mouth 
Blurred vision 
Constipation 
Nausea 
Vomiting 
Dolasetron  Diarrhoea 
Constipation 
headache  
Fatigue 
Dizziness 
Drowsiness 
Duloxetine  Nausea 
Vomiting 
Constipation 
Diarrhoea 
Dry mouth 
Insomnia 
Drowsiness 
Headache 
Dizziness 
Fatigue 
Fluoxetine Dizziness 
Sleep disturbance 
Drowsiness 
Dry mouth 
Blurred vision 
Constipation 
Nausea 
Vomiting 
Sleep disturbance  
Euphoria 
Gabapentin Diarrhoea 
Dry mouth 
Dyspepsia 
Nausea 
Vomiting 
Constipation 
Abdominal pain 
Flatulence 
Appetite changes 
Weight gain 
Hypertention 
Vasodilation 
Oedema 
Paroxetine Dizziness 
Sleep disturbance 
Drowsiness 
Dry mouth 
Blurred vision 
Constipation 
Fatigue  
Pregabalin  Dry mouth 
Constipation 
Nausea 
Vomiting 
Flatulence 
Oedema 
Dissiness 
Drowsiness 
Irritability 
Euphoria 
Fatigue 
Insomnia 
Weigh gain 
Sodium oxybate Nausea 
Vomiting 
Diarrhoea 
Peripheral oedema 
Sleep disorder 
Drowsiness 
Dissiness 
Headache 
Fatigue 
Blured vision 
Tramadol Nausea 
Vomiting 
Sleep disturbance 
Headache 
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Constipation 
Dry mouth 
Dissiness 
Drowsiness 
Euphoria 
Diarrhoea 
Fatigue 
cyclobenzaprine Dry mouth 
Dizziness 
Fatigue 
Constipation 
Drowsiness 
Nausea 
Milnacipran Blurred vision 
Nausea 
Constipation 
Vomiting  
Dry mouth 
Upper respiratory tract 
infection  
Headache 
Dizziness 
Insomnia 
Tropisetron  Headache 
Constipation 
Dizziness 
Tiredness 
Stomach pain 
Diarrhoea 
Tramadol Dizziness 
Nausea 
Constipation 
Headache 
Drowsiness 
Vomiting 
Insomnia 
Dry mouth 
Diarrhoea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
